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Tumor microenvironment comprised of extracellular matrix (ECM) and non-malignant cells 
has profound effects on cancer progression. Membrane-type matrix metalloproteinases (MT-
MMPs) expressed by both tumor and stroma cells are involved in the modulation of tumor 
microenvironment and thereby regulate tumor cell proliferation, invasion and dissemination. 
MT1-MMP is a prototype of MT-MMP family, which is overexpressed in many types of 
cancer, where it promotes tumor cell invasion through collagen-rich tissues. The biological 
functions of another member of the MT-MMP family, MT3-MMP, have remained largely 
unknown. Unlike MT1-MMP, MT3-MMP cannot cleave native collagen type I. MT3-MMP is 
expressed in the adult brain, as well as various cancer types such as brain tumors and nodular 
melanoma. The purpose of this thesis was to elucidate the functions of MT1-MMP and MT3-
MMP in melanoma cell invasion. To understand the pericellular growth regulation, we 
searched for endogenous enzymes which could release latent TGF-β from endothelial cell 
extracellular matrix. 
Neovessel formation (angiogenesis) is a prerequisite for tumor growth. Pericellular 
modulation of the ECM by MT1-MMP releases matrix-associated growth factors and 
bioactive peptides, which further affect angiogenesis and tumor cell biology. We found that 
MT1-MMP mRNA expression and activity were induced after morphological activation of 
endothelial cells, which mimics the initial phases of angiogenesis. MT1-MMP modulated 
subendothelial extracellular matrix, and cleaved latent TGF-β binding protein-1 (LTPB-1), 
with subsequent release of latent TGF-β complexes from the ECM. TGF-β can both promote 
and inhibit endothelial cell proliferation, and the opposing effects of TGF-β depend on its 
concentration. Thus, MT1-MMP-mediated LTBP-1 cleavage provides a mechanism for the 
tightly controlled release of matrix-associated TGF-β at the sites of neovessel formation.  
To elucidate the functions of MT-MMPs in melanoma cell invasion, we analyzed the 
expression of MT1-MMP and MT3-MMP from biopsies of normal human skin, benign nevi, 
and melanoma metastases. MT3-MMP was upregulated in lymph node metastases of human 
melanoma, while MT1-MMP expression was comparable in all biopsies. By culturing 
melanoma cells in 3D collagen and fibrin matrices, we found that MT3-MMP was associated 
with expansive melanoma growth in 3D collagen, but promoted their sprouting growth in 3D 
fibrin. In in vivo xenograft experiments, MT3-MMP expressing melanoma xenografts grew 
slowly, while MT3-MMP silencing enhanced tumor growth rate by over twofold. 
Interestingly, high MT3-MMP expression in murine xenografts and a human melanoma tumor 
was associated with prominent lymphatic vessel invasion but negligible blood vessel invasion 
of melanoma cells. Silencing of MT3-MMP reduced lymphatic invasion but facilitated blood 
vessel invasion of melanoma cells over ~10-fold. MT3-MMP reduced cell surface MT1-MMP 
in vitro and in vivo, resulting in limited collagen invasion in vitro and collagen accumulation 
in vivo. This suggested that low collagenolytic ability of MT3-MMP-expressing melanoma 
cells resulted in decreased blood vascular invasion. These cells invaded instead into more 
permissive lymphatic vessels. Since lymphatic vessel invasion is associated with metastatic 





Kasvaimet koostuvat syöpäsolujen lisäksi soluväliaineesta ja useista muista solutyypeistä, 
jotka myötävaikuttavat syövän kasvuun. Solukalvoon kiinnittyneet matriksin 
metalloproteinaasit (MT-MMP:t), jotka ilmentyvät sekä syöpäsoluissa että muissa strooman 
soluissa, pilkkovat solukalvon ja soluväliaineen proteiineja. Näin ollen ne muokkaavat 
syöpäsolujen proliferaatiota ja invaasiota. MT1-MMP on tämän entsyymiperheen prototyyppi. 
Se osallistuu luuston ja verisuoniston kehitykseen sekä kollageenin normaaliin kiertoon 
aikuisessa elimistössä. MT1-MMP:tä ilmennetään monessa syövässä, joissa se lisää 
syöpäsolujen invaasiota kollageenipitoisten kudosten läpi. Tämä tehostaa etäpesäkkeiden 
muodostumisen. MT3-MMP on MT1-MMP:n läheinen homologi, joka ei pysty pilkkomaan 
tyypin I kollageenia, mutta sen sijaan pilkkoo fibriiniä. Sitä ilmennetään  aikuisen aivoissa ja 
muutamissa syöpätyypeissä, kuten aivokasvaimissa ja nodulaarisessa melanoomassa. 
Väitöskirjatyöni tarkoituksena on ollut selvittää MT1-MMP:n ja MT3-MMP:n vaikutuksia 
melanoomasolujen invaasioon. Tähän liittyen selvitimme mitkä endogeeniset entsyymit 
voivat vapauttaa latenttia transformoivaa kasvutekijä-betaa (TGF-β) endoteelisolujen 
soluväliaineesta.  
Soluväliaineen proteiinien pilkkominen voi vapauttaa niihin kiinnittyneitä kasvutekijöitä 
ja muita bioaktiivisia peptidejä. Tuloksemme osoittavat että MT1-MMP pilkkoo latenttia 
TGF-β:aa sitovaa proteiinia (LTBP-1) verisuonia verhoavien, eli endoteelisolujen, 
soluväliaineesta. LTBP-1 sitoo TGF-β:aa ja kiinnittyy soluväliaineen proteiineihin. LTBP-1:n 
pilkkominen vapauttaa TGF-β -komplekseja soluväliaineesta, mikä myötävaikuttanee tämän 
latentin kasvutekijän aktivaatioon. TGF-β:n vaikutukset muodostuvaan verisuontistoon 
riippuvat sen pitoisuudesta. TGF-β:n vapauttaminen ja aktivoiminen soluväliaineesta MT1-
MMP:n välityksellä voi säädellä uusien  verisuonien muodostumista. 
Melanooma on yleistymässä oleva ihosyöpätyyppi, ja levinneen melanooman 
hoitomahdollisuudet ovat rajalliset. MT3-MMP:aa ilmennetään nodulaarisessa 
melanoomassa, joka on huonoennusteisin melanoomatyyppi. Analysoimme tässä MT3-
MMP:n vaikutuksia melanoomasolujen invaasiotapahtumaan käyttäen in vitro 
invaasiokokeita ja hiirikokeita. MT3-MMP:n ilmentyminen oli lisääntynyt ihmisen 
melanooman imusolmuke-etäpesäkkeissä. Melanoomasolujen kasvattaminen 
kolmiulotteisissa geeleissä osoitti, että MT3-MMP esti solujen invasiivista kasvua 
kollageenissa edistämällä pyöreiden pesäkkeiden kasvua. Fibriinissä MT3-MMP sen sijaan 
edisti invaasiivista kasvua. Vastaavasti MT3-MMP:tä ilmentävät melanoomaksenograftit 
kasvoivat hitaasti hiirten subkutaanisissa kudoksissa, kun taas MT3-MMP:n hiljentäminen 
nopeutti niiden kasvua noin kaksinkertaiseksi. MT3-MMP vähensi solupinnalla olevan MT1-
MMP:n tasoja in vitro ja in vivo, mikä johti vähentyneeseen kollageenin pilkkomiseen ja 
kollageenin määrän nousuun kasvainten sisällä. Havaitsimme MT3-MMP:tä ilmentävissä 
ksenografteissa ja ihmisen melanoomassa kasvainsolujen voimakkaan invaasion imusuoniin. 
MT3-MMP:n hiljentäminen puolestaan esti imusuoni-invaasiota ja lisäsi verisuoni-invaasiota 
noin kymmenkertaiseksi. Ihmisen melanoomissa, matala MT1-MMP ja korkea MT3-MMP 
liittyivät melanoomasolujen kohesiiviseen kasvuun pyöreinä pesäkkeinä, kun taas korkea 
MT1-MMP yhdistettynä matalaan MT3-MMP:hen liittyi diffuusiin invasiiviseen kasvuun. 
Koska melanoomasolujen imusuoni-invaasio liittyy etäpesäkkeiden muodostumiseen, MT3-




Опухолевая микросреда состоит из внеклеточного матрикса и нераковых клеток, 
которые влияют на развитие рака. Мембрано-ассоциируемые матриксные 
металлопротеиназы (МТ-ММП) являются протеолитическими ферментами, 
способствующими метастазированию раковых клеток. МТ1-ММП экспрессируется во 
многих видах опухолей. В отличие от МТ1-ММП, МТ3-ММП не способен расщеплять 
коллаген I-типа. Этот фермент экспрессируется в тканях головного мозга человека, а 
так же в некоторых видах опухолей, таких как рак головного мозга и узловая меланома. 
В этой диссертации была исследована роль МТ1-ММП и МТ3-ММП в инвазии клеток 
меланомы. Также были изучены ферменты способствующие освобождению 
трансформирующего ростового фактора бета (ТРФбета-1) из внеклеточного матрикса 
эндотелиальных клеток.   
Образование новых сосудов является необходимым условием для роста опухоли. 
МТ1-ММП модулирует внеклеточный матрикс, освобождая из него факторы роста и 
биологически активные пептиды, которые в свою очередь влияют на развитие 
кровеносных сосудов и рост раковых клеток. Мы обнаружили, что МТ1-ММП 
освобождает ТРФбета-1 из внеклеточного матрикса посредством расщепления 
латентного ТРФбета-связывающего белка (LTBP-1), с которым ТРФбета-1 
ассоциирован. ТРФбета-1 может как индуцировать, так и ингибировать пролиферацию 
эндотелиальных клеток, и эти противоположные эффекты ТРФбета-1 зависят от его 
концентрации. Таким образом, МТ1-ММП с помощью расщепления LTBP-1 регулирует 
концентрацию активного ТРФбета в местах образования новых сосудов.  
Для выяснения функций МТ3-ММП в инвазии клеток меланомы, мы 
проанализировали экспрессию МТ3-ММП в биопсиях здоровой кожи человека, 
доброкачественных родинок, и метастаз меланомы. Экспрессия МТ3-ММП была 
повышена в метастазах меланомы в лимфатических узлах. Путем культивирования 
клеток меланомы в 3-х мерном коллагене и фибрине мы обнаружили, что МТ3-ММП 
ингибировал инвазию клеток меланомы в коллагене, но способствовал их инвазии в 
фибрине. В привитых мышам опухолях меланомы, опухоли экспрессирующие МТ3-
ММП росли в 2 раза медленнее чем опухоли, из которых МТ3-ММП был удален. 
Любопытно, что экспрессия МТ3-ММП была связана со значительной инвазией клеток 
меланомы в лимфатические сосуды, а удаление МТ3-ММП привело к инвазии в 
кровеносные сосуды. МТ3-ММП значительно уменьшил количество МТ1-ММП на 
клеточной мембране клеток меланомы, что привело к замедлению инвазии в 3-х 
мерном коллагене in vitro и аккумуляции коллагена in vivo. Таким образом, в данной 
работе показано, что клетки меланомы экспрессирующие МТ3-ММП обладают слабой 
способностью расщеплять коллаген, что приводит к неэффективной инвазии в 
кровеносные сосуды. Тем не менее, эти клетки растут расширяющимися колониями и 
способны эффективно инвазировать в лимфатические сосуды с более тонкими 
стенками. Ввиду того, что инвазия лимфатических сосудов связана с 
метастазированием меланомы, МТ3-ММП может послужить новым маркером для 
определения прогноза меланомы и выявления пациентов нуждающихся в агрессивной 
терапии уже на ранних стадиях. 
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Cancer cells utilize matrix metalloproteinases (MMPs) to grow, traverse interstitial tissue, and 
disseminate to distant organs via lymphatic or blood vessels. In order to get access to oxygen 
and nutrients, growing tumors induce new blood vessel formation (angiogenesis), a process 
where MMPs are also involved. Membrane-type matrix metalloproteinases (MT-MMPs) are 
cell surface proteases which mediate both pericellular proteolysis and cleavage of other cell 
surface proteins. Malignant melanoma is one of the numerous cancer types in which MT-
MMPs are associated with the disease progression. MT1-MMP is specifically expressed at the 
invading edge of melanoma tumors, and is linked to metastatic form of the disease. MT3-
MMP is overexpressed in the most aggressive melanoma subtype, nodular melanoma. Since 
metastatic form of melanoma is highly resistant to current treatment modalities, it is essential 
to unravel the factors which lead to the acquirement of the metastatic ability by melanoma 
cells. Furthermore, new prognostic markers which can be assessed from the primary tumor 
and can predict metastatic progression are needed in order to more accurately select patients 
who would benefit from sentinel lymph node biopsy and early aggressive treatment. In this 
thesis we analysed the functions of MT1-MMP in endothelial cells, and assessed the functions 
of MT3-MMP in melanoma cell invasion, growth and intravasation. These results will help to 
understand the role of these MT-MMPs in pericellular proteolysis, growth factor release from 






Malignant melanoma is not the most frequent skin cancer, but beyond doubt the most lethal 
one. Every year ~700 Finns acquire this disease. The incidence of melanoma is rising around 
the world. From 1953 through 2003, the incidence of skin melanoma increased in Finland 
from 1.5 to 12.8 per 100,000 among men and from 1.8 to 10.4 per 100,000 among women 
(Stang et al., 2006). The median age of patients at diagnosis is about 57, which is 10 years 
less than that of cancer patients in general (Rager et al., 2005). The mean 5-year survival of 
melanoma patients in Finland is 83% for men and 88% for women 
(http://www.cancer.fi/syoparekisteri/tilastot/). 
The four most common clinicopathological subtypes of cutaneous melanoma are 
superficially spreading melanoma (SSM, 70%), nodular melanoma (NM, 15%), lentigo 
maligna (13%), and acral lentiginous melanoma (2-3%) (Bradford et al., 2009). SSM grows 
first radially in the epidermis (radial growth phase, Breslow index <0.75 mm, Fig. 1), 
gradually gaining the ability to grow vertically into the dermis and further metastasize 
13 
(vertical growth phase, Fig. 1). Histologically SSM is characterized by single cells or nests of 
atypical melanocytes seen in all layers of epidermis and dermis, with no sharp lateral margins 
(Smoller, 2006). Mitotic activity, lack of full maturation, vesicular nuclei with prominent 
nucleoli, and inflammatory response are features which help to differentiate malignant 
melanoma of this type from benign nevi (Smoller, 2006). ABCD-criteria (asymmetry, border, 
color, and diameter) have been introduced to help the diagnosis of SSM. NM grows in the 
dermis, often pushing epidermis up forming a clear nodule, and is frequently amelanotic 
(Chamberlain et al., 2002). This subtype lacks radial growth phase. Instead, these tumors 
invade deeper dermis at the early stage, and have often metastasized at the time of diagnosis. 
The diagnosis of NM might be delayed due to the lack of typical ABCD-features of 
melanoma (Lallas et al., 2012). Therefore, additional EFG-criteria (elevation, firmness, and 
growth) have been introduced, but their diagnostic specificity remains unknown (Kelly et al., 
2003). The presence of both blue and black regions as observed by dermoscopy may predict 
the malignant nature of the nodular tumor (Lallas et al., 2012). Usually NM affects middle-
aged people, men more often than women, and occurs most frequently on trunk (Smoller, 







Figure 1. Phases of melanoma progression. Modified from Gremel et al., 2009. 
 
2.2 Staging and prognosis 
 
In 1970 Alexander Breslow developed a still widely used method for estimating melanoma 
prognosis by measuring tumor thickness under the microscope (Breslow, 1970). Breslow 
thickness is the most significant feature of primary tumor which affects survival (Balch et al., 
2009). The next important predictors are the number of mitoses and ulceration status. Thus, 
10-year survival for T1 (≤1 mm) non-ulcerated melanoma is 92%, while for T4 melanoma (>4 
mm) it is ~40% or ~55%, depending on the ulceration status (Balch et al., 2009). Breslow 
thickness also predicts sentinel lymph node metastasis. Thus, in T1 melanoma 1% of patients 
14 
and in T4 melanoma 35.5% of patients have micrometastasis in the sentinel lymph nodes 
(Lens et al., 2002).  
The 7
th
 version of the TNM classification and staging system introduced by American 
Joint Committee on Cancer (AJCC) is presented in Table 1 (Balch et al., 2009). When the 
disease has spread, the stage is the most powerful prognostic factor (Balch et al., 2009). 
Staging is defined by combining tumor thickness, ulceration status, mitosis rate per mm
2
, 
involvement of regional and distant lymph nodes, as well as the presence of distant 
metastases. The most powerful predictors for prognosis of spread disease (stage III) are the 
number of metastatic lymph nodes, micro- vs. macrometastasis, Breslow thickness, and 
ulceration status (Balch et al., 2009). 
Melanoma metastases are detected first in the sentinel lymph node, which is the first 
lymph node receiving lymphatic liquid from the area of the tumor. Sentinel lymph node 
mapping and biopsy has been introduced in 1992, and is currently a common practice 
worldwide (Morton et al., 1992). Sentinel lymph node biopsy is the most important prognostic 
procedure in melanoma patients with T2-4 primary tumors (Vuylsteke et al., 2003; Yee et al., 
2005). Thus, 5-year survival of SLN-negative patients is 90-92%, and for SLN-positive – 56-
67% (Vuylsteke et al., 2003; Yee et al., 2005). If SLN is positive, all regional lymph nodes 
are commonly evacuated. After the resection of the regional lymph nodes, 34% of patients 
have no recurrence during 25 years of follow-up, 44 % have distant recurrence, and 22% local 
or regional recurrence (White et al., 2002).  
 
Table 1. TNM classification and staging by AJCC. Modified from Balch et al., 2009. 
 
Stage T Thickness Ulceration status  
     
0 T in situ    
IA T1a ≤ 1.0 mm                - and mitoses <1/mm
2
  
IB T1b                 + or mitoses ≥1/mm
2
  
IB T2a 1.01-2.0 mm -  
IIA T2b  +  
IIA T3a 2.01-4.0 mm -  
IIB T3b  +  
IIB T4a > 4.0 mm -  
IIC T4b  +  
     
Stage N No of metastatic nodes Ulceration status 
Nodal metastatic 
mass 
     
IIIA N1a 1 node - micrometastasis 
 N2a 2-3 nodes - micrometastasis 
IIIB N1a 1 node + micrometastasis 
 N2a 2-3 nodes + micrometastasis 
 N1b 1 node - macrometastasis 
 N2b 2-3 nodes - macrometastasis 
 N2c 2-3 nodes - 
in transit/satellite w/o 
metastatic nodes 
IIIC N1b 1 node + macrometastasis 
 N2b 2-3 nodes + macrometastasis 
 N2c 2-3 nodes + 
in transit/satellite w/o 
metastatic nodes 
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 N3 4 or more nodes Any  
     
Stage M Site Ulceration status Serum LHD 
     
IV M1a 
Distant skin, subcutaneous or 
distant nodes 
Any Normal 
 M1b Lung Any Normal 
 M1c All other visceral Any Normal 
 M1c Any Any Elevated 
 
 
Clark invasion level has not been included to the newest version of TNM classification and 
staging, but is still widely used method to depict invasion depth of primary melanoma (Clark 
et al., 1969). Thus, in level I melanoma tumor cells have not crossed the basement membrane, 
in level II melanoma cells are detected in the upper part of the papillary dermis, in level III 
they are detected across the whole thickness of papillary dermis, in level IV – in the reticular 
dermis, and in level V – in the subcutaneous tissue. 
 
2.3 Genetic aberrations in melanoma 
 
Melanoma arises from a benign or dysplastic naevus, or directly de novo without a precursor 
lesion. Ultraviolet (UV) radiation is the strongest factor predisposing to melanoma. It induces 
both melanocyte proliferation and DNA damage. Mutations in the Ras-Raf-MAPK pathway 
are among the most frequent mutations observed in melanoma (Davies et al., 2002). In this 
pathway, activation of receptor tyrosine kinases triggers guanosine triphosphate (GTP) 
loading of Ras, which then recruits serine threonine Raf kinases to the cell membrane. 
Activated Raf phosphorylates MEK1 and MEK2 kinases which activate Erk1/2 kinases. 
These translocate into the nucleus where they induce transcription of the genes involved in 
cell-cycle progression (Pearson et al., 2001). Ras can signal also through 
phosphatidylinositol-3 kinase (PI-3K) or phospholipase (PLC) pathways (Cullen, 2001; Katz 
and McCormick, 1997). The Ras family includes N-ras, H-ras, and K-ras kinases. The Raf 
family consists of three isoforms, Raf-1 (C-Raf), A-Raf, and B-Raf. BRAF mutation is seen in 
50-81% of benign nevi (Wu et al., 2007), but additional mutations are needed for malignant 
transformation. NRAS mutation is detected in 21% of SSM, in 31% of NM (Platz et al., 2008), 
in 9% of acquired benign nevi, and in 35% of congenital nevi (de Snoo and Hayward, 2005). 
Mutations in Ras-Raf-MAPK pathway induce constitutive activation of ERK1/2 kinases, 
which induces melanoma cell proliferation, tumor invasion and metastasis. 66% of 
melanomas have mutated BRAF (Davies et al., 2002), and 80% display mutations in either 
BRAF or NRAS (Platz et al., 2008). The V600E accounts for 90% of BRAF mutations detected 
in human melanoma (Platz et al., 2008). Interestingly, this mutation induces the senescence of 
naevus cells (Michaloglou et al., 2005).  
One of the pathways proposed to be responsible for the eventual malignant 
transformation of melanocytes is the cyclin-dependent kinase inhibitor 2A (CDKN2A) 







 inhibits cyclin-dependent kinases CDK4 and CDK6, which promote 
cell cycle progression by phosphorylating Retinoblastoma (Rb) protein. High proportion of 
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melanoma cell lines exhibit inactivation of CDKN2A gene or activating mutations of CDK4 
gene, which both lead to uncontrolled CDK4 and CDK6 activities (Walker et al., 1998). 
Reduced expression of p16
INK4a
 in melanoma has been associated with higher Clark invasion 
levels, melanoma progression, and increased risk of the disease relapse (Straume et al., 2000; 
Talve et al., 1997).  
PTEN (phosphatase and tensin homolog deleted on chromosome 10) is a tumor 
suppressor which dephosphorylates PIP3 (phosphatidylinositol-4,5,6-triphosphate). Loss of 
PTEN leads to increased PIP3 activity, which further activates PI3K/Akt signaling pathway, 
leading to increased cell proliferation and survival. Loss of PTEN is observed in 70% of 
melanoma cell lines, and it is epigenetically silenced in 30-40% of metastatic melanomas 
(Mehnert and Kluger, 2012). 
Molecules involved in the transition from RGP to VGP melanoma phases include 
MMP-1 (Blackburn et al., 2009), αvβ3 integrin (Seftor, 1998), PAR-1 (Tellez and Bar-Eli, 
2003), VEGF (Streit and Detmar, 2003), and loss of AP-2 transcription factor (Bar-Eli, 2001). 
Loss of AP-2 is associated with the upregulation of its target genes, such as MCAM and 
MMP-2, both of which have been implicated in melanoma progression (Tellez and Bar-Eli, 
2003). In contrast, Haqq et al (2005) observed only the downregulation of some genes during 
the RGP/VGP transition, such as cadherin-3, MMP10, integrin α2, and laminin γ2 (Haqq et 
al., 2005). Maspin is a serine protease inhibitor that inhibits angiogenesis and is also 
downregulated in RGP/VGP transition (Chua et al., 2009). 
 
3. Extracellular matrix 
 
All tissues in the body are composed of cells and their extracellular matrix. Extracellular 
matrix was earlier considered merely as structural support to organs, but later has been 
recognized as an active component of tissues. It stores growth factors and other bioactive 
molecules (Taipale and Keski-Oja, 1997), acts as a barrier for cell invasion or a scaffold for 
cell migration along its fibers, and provides signalling cues to the cells via cell surface 
receptors (Lu et al., 2012). Perturbations in ECM deposition, composition, or turn-over may 
lead to such devastating diseases as fibrosis and cancer. Extracellular matrices can be roughly 
divided to interstitial matrices and basement membranes (Lu et al., 2012). Provisional matrix 
is a temporary matrix formed at the sites of tissue injury, or tumor/host interface. 
 
3.1 Interstitial matrix 
 
Interstitial matrix is composed of a hydrated gel-like ground substance and fibers (collagens 






3.1.1 Ground substance 
 
Ground substance is an amorphous material composed of glycosaminoglycans (GAGs), 
proteoglycans and glycoproteins (Dudas and Semeniken, 2012). The water in hydrated ground 
substance permits the rapid exchange of nutrients and waste products. GAGs are 
polysaccharides composed of chains of repeating disaccharide units. Almost all GAGs are 
sulfated, except hyaluronan, including keratin sulfate, heparan sulfate, heparin, and 
chondrotin-4-sulfate. GAGs are usually covalently linked to proteins to form proteoglycans. 
Hyaluronan contributes to cell migration, and also promotes malignant progression of several 
cancers (Bharadwaj et al., 2009; Pasonen-Seppänen et al., 2012; Sironen et al., 2011).  
Proteoglycans are large macromolecules which look like bottle brush, with the protein 
core resembling the stem, and GAGs projecting from its core resembling the bristles of the 
brush. Examples of proteoglycans are aggrecan, which is found in cartilage and other 
connective tissue, perlecan, found in vascular ECM, biglycan, found in bone and cartilage, 
and decorin, which modulates collagen fibril formation as well as affects the bioactivity of 
TGF-β (Danielson et al., 1993). Several aggrecan molecules can attach to a single, up to 20 
µm long hyaluronan molecule non-covalently. This complex can reach the molecular weight 
of several hundred million daltons. Proteoglycans resist the compression of the tissue and 
retard the movement of bacteria or metastatic cells. Many bacteria, such as Staphylococcus 
aureus, secrete hyaluronidase, which cleaves hyaluronan and presumably helps the spread of 
the bacteria (Makris et al., 2004).  
Syndecans are an example of cell membrane proteoglycans. They modulate the adhesion 
of integrins to various ECM molecules (Beauvais and Rapraeger, 2003). Syndecan-1 inhibits 
tumor cell invasion by reducing MT1-MMP mRNA (Vuoriluoto et al., 2011), while MT1-
MMP induces breast carcinoma cell proliferation and fibrosarcoma cell migration by cleaving 
syndecan-1 (Endo et al., 2003; Su et al., 2008). Syndecan-4 is a component of focal adhesions 
and a co-receptor of α5β1 integrin (Bass et al., 2008; Woods et al., 2000). It drives focal 
adhesion formation by binding to fibronectin and activating PKC-α (Woods et al., 2000).  
Glycosylated proteins are called glycoproteins. Fibronectin is a large dimeric 
glycoprotein composed of two polypeptides, which are attached to each other at their carboxyl 
ends by disulfide bond and forming thus V-shaped molecule. It has binding sites for 
collagens, heparin, heparan sulfate, hyaluronan, and integrins (Engvall et al., 1978). 
Fibronectin is abundant in plasma, interstitial matrix and basement membrane (Ruoslahti and 
Vaheri, 1974). It promotes lung metastasis in xenograft models by incorporating into the 
blood clots around the tumor emboli and stimulating tumor cell invasion via αvβ3 integrin 




Collagens are large extracellular molecules with various functions in maintaining tissue 
structure. Collagens and their cleavage products have also signalling functions, for example in 
angiogenesis. A total of 28 collagen proteins have been described in human to date. All 
collagens consist of three α-chains, each of which contains collagenous domain with series of 
Gly-X-Y sequences. Non-collagenous domain (NC) is important for collagen fiber assembly. 
Three α-chains are each coiled into a left-handed helix, and then get twisted around a common 
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axis to form a right-handed triple helix. Glycine at every third position is important for 
packing structure. Proline is often found in the X position and 4-hydroxyproline in the Y 
position (Myllyharju and Kivirikko, 2004). Collagen-like triple helical domains can be found 
in 20 other proteins, for example subcomponent of complement C1q (Heino, 2007). 
Structurally collagens can be divided to 8 groups. We will restrict this review to the groups 
which are expressed in the skin.  
Fibril-forming collagens (type I, II, III, V, XI, XXIV and XXVII) provide tissues with 
tensile strength. Collagen type I is the most abundant protein in the body. It is expressed in 
skin, bone, and tendons. It is a heterotrimer consisting of two α1 and one α2 chains. Collagen 
type III is a homotrimer and, in addition to skin, is found in the spleen, liver, cardiovascular 
system and lung. Type II and XI are expressed in the cartilage. Collagen type II is a 
homotrimer consisting of three α1 chains. Collagen fibrils can contain more than one collagen 
type. Thus, collagen type I fibrils can contain type III, V and XII collagen fibrils (Myllyharju 
and Kivirikko, 2004). Fibril-forming collagens are secreted as procollagens with propeptides 
at both ends, which are cleaved by procollagen peptidases. Then, the collagen molecules self-
assemble in head-to-tail direction into fibrils. Lysyl oxidase catalyzes covalent crosslinking of 
collagen molecules inside the fibrils. Subsequently, the fibrils arrange into fibers. Mutations 
in type I collagen cause osteogenesis imperfecta and Ehlers-Danlos syndromes, and mutations 
in type III collagen are behind the Ehlers-Danlos syndrome and arterial aneurysms 
(Myllyharju and Kivirikko, 2004). 
Type VII collagen is a homotrimer and the main component of anchoring fibrils that 
connect basement membranes to the papillary dermis. The mutations in COL7A1 account for 
dystrophic epidermolysis bullosa (Ryynanen et al., 1991), and in epidermolysis bullosa 
acquisita autoantibodies against collagen type VII decrease the number of anchoring fibrils, 
making the skin fragile and predisposed to blistering (Lapiere et al., 1993). 
 
3.1.3 Elastic fibers 
 
Elastic fibers provide mechanical elasticity to the organs, such as the lung, skin, and the large 
arteries. Under electron microscopy they appear as twisted or straight strands (Ushiki, 2002). 
Elastic fibers can be stretched to one and a half of their length and, when released, return to 
their resting length. They are produced by fibroblasts and smooth muscle cells of blood 
vessels. The core of these fibers composed of elastin is surrounded by microfibrils. 
Tropoelastin is a soluble precursor of elastin, which is deposited on the preformed network of 
microfibrils, and becomes cross-linked by lysyl oxidase (Kielty et al., 2002). Microfibrils are 
mainly composed of fibrillins, members of fibrillin/LTBP family. Three fibrillins have been 
identified to date. They are large glycoproteins (~350 kDa), mainly composed of EGF-repeats 
and 8-cysteine motifs, which can bind to integrins via RGD motif (Robinson and Godfrey, 
2000). Microfibril associated glycoprotein-1 (MAGP-1) is a 31 kDa glycoprotein, which is 
covalently linked to the microfibrils. Moreover, it binds tropoelastin and collagen type VI, 
and may thus mediate tropoelastin deposition as well as the association of collagen type VI 
and microfibrils, seen in soft connective tissue (Robinson and Godfrey, 2000). 
Mutations in fibrillin-1 gene account for the Marfan syndrome and Marfan-like 
abnormalities (Robinson and Godfrey, 2000). Marfan syndrome is an autosomal dominant 
disease characterized by ocular, skeletal and cardiovascular defects. Its typical features 
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include scoliosis, chest wall deformity, tall stature, hypermobility of the joints and ligaments, 
mitral valve prolapse, and aortic aneurysms (Robinson and Godfrey, 2000). Mutations in 
fibrillin-2 cause congenital contractural arachnodactyly, or Beal’s syndrome, characterized by 
marfanoid appearance, long fingers, contractures of elbows, knees and hips, and 
underdeveloped muscles (Viljoen, 1994).  
The composition and organisation of elastic fibers vary in different tissues. In the aorta 
they fuse to form sheets, in the lungs elastic fibers form a thin branched network, in the 
reticular dermis they are organized horizontally, while in the papillary dermis elastic fibers 
are perpendicular merging with oxytalan fibers which connect them to the basement 
membrane (Kielty et al., 2002; Ushiki, 2002). Oxytalan fibers are microfibrils composed of 
fibrillins, which also connect lymphatic vessels to underlying elastic fibers, preventing 
lymphatic vessels from collapsing (Gerli et al., 1990). 
 
3.2 Basement membranes 
 
Basement membranes (BMs) are amorphous sheet-like structures, which consist of about 50 
proteins, but collagens comprise ~50% of their protein mass. BM regulates cell polarity of 
various cell types, including epithelial, endothelial, muscle cells, and peripheral nerves, 
separating them from underlying collagenous tissue. Main components of BM are collagen 
type IV, laminins, nidogen, proteoglycan perlecan which has heparan sulfate side chains, 
fibronectin, and collagen type XV and XVIII (Kalluri, 2003).  
Collagen type IV heterotrimers do not form fibrils, because their propeptides do not get 
removed. Instead, heterotrimers assemble into hexamers via their NC1 domains, which further 
associate into sheet-like meshwork via 7S domains (Kalluri, 2003). Six different genes encode 
six α-chains (α1- α6), which can form at least seven different heterotrimers (Kalluri, 2003). 
Collagen type IV is found mainly in basement membrane, but can be also accumulated in 
tumor ECM. Mutations in collagen type IV lead to Alport syndrome with defective 
glomerular basement membrane (Ortega and Werb, 2002). In Goodpasture syndrome, 
autoantibodies are produced against α3 chain of collagen type IV, resulting in severe 
glomerulonephritis and pulmonary haemorrhage (Hudson et al., 1993). Tumstatin, the NC1 
domain of collagen type IV α3 chain, inhibits angiogenesis (Petitclerc et al., 2000). Another 
anti-angiogenic collagen IV peptide derived from NC1 domain of α1 chain, arresten, inhibits 
in addition to angiogenesis tumor growth in mice and tumor metastasis (Colorado et al., 2000; 
Nyberg et al., 2008). Interestingly, the NC1 domain of α4 chain, tetrastatin, reduces the 
expression of membrane-type-1 matrix metalloproteinase (MT1-MMP), which is involved in 
tumor cell invasion. This leads to reduced proliferation and invasion of melanoma xenografts 
(Brassart-Pasco et al., 2012).   
Collagens type XV and XVIII are proteoglycans called multiplexins, and participate in 
the stabilization of the basement membrane. They are interesting in the regards that cleavage 
products of their NC domains generate restin (Ramchandran et al., 1999) and endostatin 
(O'Reilly et al., 1997; Wickstrom et al., 2002), respectively, which both display anti-
angiogenic activities. Mutation in α1 chain of collagen XVIII results in Knobloch syndrome, 
characterized by abnormalities in retinal vasculature, blindness, and neural tube closure 
defects (Seppinen and Pihlajaniemi, 2011). 
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The self-assembly of BM begins when integrins initiate laminin polymer deposition. 
Then, collagen type IV connects to laminin polymers via nidogen bridging (Kalluri, 2003). 
Laminin is a large glycoprotein composed of three polypeptide chains, α, β, and γ, which can 
assemble into at least 15 heterotrimers making up cross-like, Y-shaped, or rod-shaped 
structures (Miner, 2008). Laminin binds to heparan sulfate, type IV collagen, nidogen, and 
cell membrane. The variety of existing isoforms of laminin, collagen type IV and 
proteoglycans permits the diversity in the BM composition in different organs, supporting 
tissue plasticity and different functions (Kalluri, 2003).  
 
3.3 Provisional matrix 
 
Provisional matrix is a temporary connective tissue formed at the sites of injury, such as skin 
wound. Furthermore, it can be observed around the growing tumor. The initial response to 
tissue injury is hemostasis, or coagulation response. Exposed collagen activates platelets 
which adhere to ECM, secrete clotting factors, and aggregate with each other (Reinke and 
Sorg, 2012). Activated coagulation cascade results in the activation of thrombin, which 
converts circulating fibrinogen to fibrin. Fibrin forms a meshwork between the platelets, 
which further strengthens their aggregation. Formed provisional matrix is composed of fibrin, 
fibronectin, vitronectin, and thrombospondins. It acts as a scaffolding matrix for invasion of 
leukocytes, keratinocytes, fibroblasts and endothelial cells. Platelets and leukocytes release 
inflammatory cytokines and growth factors, such as interleukins, TNF-α, bFGF, TGF-β, 
VEGF-A, HIF-1α and IGF-1 (Reinke and Sorg, 2012). This results in transformation of 
fibroblasts to myofibroblasts, induction of collagen secretion, angiogenesis, and re-
epithelialization. The provisional matrix is then replaced by the acute granulation tissue, 
which is composed of collagen, fibroblasts, and inflammatory cells, and is highly vascular. As 
a last phase of wound healing, granulation tissue is matured to avascular and acellular scar 
(Reinke and Sorg, 2012). 
Fibrinogen is a hexamer which consists of two copies of its three chains: Aα, Bβ, and γ, 
(AαBβγ)2. Three chains of human fibrinogen are encoded by three different genes (Fish and 
Neerman-Arbez, 2012). They are expressed by hepatocytes, which secrete glycosylated 
fibrinogen hexamers (~340 kDa) into the circulation. Blood plasma contains between 1.5 to 
3.5 g/l of fibrinogen. Activated thrombin cleaves Aα and Bβ chains, exposing specific sites 
which initiate rapid fibrinogen polymerization. This leads to the formation of fibrin fibers 
(Standeven et al., 2005). The determinants of fibrin structure are pH and various molecules, 
such as calcium, chloride ions, albumin, and collagen, among others (Standeven et al., 2005). 
Activation of coagulation cascade sets into motion a fibrinolytic cascade, which will limit the 
size of a blood clot. Fibrin promotes the conversion of plasminogen to plasmin by tissue 
plasminogen activator (t-PA) (Standeven et al., 2005). Plasmin cleaves fibrin and interferes 
with its polymerization. Fibrin degradation products act also as anticoagulants, providing an 





3.4 ECM-sequestered growth factors 
 
The targeting of growth factors to the ECM provides means for their rapid activation in a 
spatially and temporally regulated manner. Growth factors such as VEGFs, IGFs, FGFs, 
HGF, and TGF-βs can associate with ECM molecules or heparan sulfate (Taipale and Keski-
Oja, 1997). We will restrict the current review to TGF-β, the release of which from the ECM 
has been addressed in this thesis. 
 
3.4.1 Structure of TGF-βs 
 
Transforming growth factor β and its receptors are expressed ubiquitously in all metazoans, 
and in humans in almost all cell types. The effects TGF-β exerts on the cells are very 
complex, sometimes opposing, and depend on growth factor concentration, cell type and 
microenvironmental factors (Massague, 2012). TGF-β was first identified as an activity which 
induced anchorage-independent growth of fibroblasts in soft agar, a phenomenon closely 
associated with the malignant transformation (de Larco and Todaro, 1978). TGF-β precursor 
was cloned in 1985 (Derynck et al., 1985), and the receptor for TGF-βs was identified in 1982 
(Massague et al., 1982). TGF-β belongs to a large TGF-β superfamily of at least 30 members 
including bone morphogenic proteins (BMPs), growth differentiation factors (GDFs), Nodal, 
and inhibins/activins (Massague, 2012).  
Three different TGF-β proteins have been identified and cloned in mammals. Their 
sequences share 71-76% similarities, and they have different expression patterns and affinity 
to TGF-β receptors. TGF-β1 knockout mice die postnatally at about day 20 from the 
multifocal inflammation, tissue necrosis and organ failure (Kulkarni et al., 1993; Shull et al., 
1992). TGF-β2 knockout mice die perinatally and exhibit cardiac, lung, craniofacial, limb, 
spinal column, eye, inner ear and urogenital defects (Sanford et al., 1997). TGF-β3 knockout 
mice die within 20 h from birth, and exhibit defects in lung maturation and cleft palates with 
100% penetrance (Kaartinen et al., 1995). 
TGF-β1 is a prototype of TGF-β family. It is translated as a 390-amino acid precursor 
protein, which is cleaved by furin generating 112-amino-acid TGF-β1 and 249-amino-acid 
latency associated peptide (LAP), to which TGF-β1 is non-covalently linked forming small 
latent TGF-β1 complex (SLC, Fig. 2, Dubois et al., 1995; Gentry et al., 1988). Both TGF-β1 
and LAP are disulfide-linked dimers. Further, SLC is covalently linked to latent TGF-β1 
binding protein (LTBP) by disulfide links forming large latent TGF-β complex (LLC, Fig. 2, 
Miyazono et al., 1988; Tsuji et al., 1990). LTBP facilitates the secretion of the complex and 






Figure 2. Formation of large latent complex of TGF-β. LAP, latency associated peptide, 
SLC, small latent complex, LLC, large latent complex. Modified from Hyytiäinen et al., 2004. 
 
 3.4.2 Structure of LTBPs 
 
LTBPs are members of LTBP-fibrillin family consisting of LTBPs 1-4 and fibrillins 1-3 (Fig. 
3). LTBPs contain 15-20 EGF-like repeats, and four 8-cysteine repeats (including hybrid 
domain), which are found only in LTBP-fibrillin family. LAP is covalently bound to the third 
8-cys repeat of LTBPs 1, 3 and 4 in ER (Saharinen et al., 1999). EGF-like repeats mediate 
protein-protein interactions, and N-terminal region and parts of C-terminal region of LTBPs 
associate with ECM (Taipale et al., 1994; Unsöld et al., 2001).  
LTBP-1 isolated first from platelets was characterized as a 125-160 kDa protein, which 
is bound by disulfide bonds to LAP (Miyazono et al., 1988). LTBP-1 cloned from fibroblasts 
was larger, 170-190 kDa protein, which was named LTBP-1L, the long form (Kanzaki et al., 
1990). LTBP-1L is extended in its N-terminal domain (Fig. 3), and assembles with ECM 
more efficiently than LTBP-1S (Olofsson et al., 1995). The expression of LTBP-1S (short 
form) and LTBP-1L are driven by different promoters (Koski et al., 1999). LTBP-1L is 
expressed mainly in the heart, kidney, placenta and prostate, and LTBP-1S is detected in 
addition in the lung, spleen, stomach, ovary, testis and skeletal muscles (Olofsson et al., 
1995). LTBP-1 facilitates the secretion of TGF-β and correct folding of SLC in certain cell 
types (Miyazono et al., 1991), but some cells, such as glioblastoma cells and osteoblasts, 
secrete TGF-β mainly without LTBP-1, as SLC (Dallas et al., 1994; Olofsson et al., 1992). 
Over 90% of LTBP-1 is secreted without TGF-β, indicating that it has also TGF-β -
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independent functions (Kwak et al., 2005). Thus, LTBP-1 is expressed in the bone, where it 
colocalizes with microfibrils (Dallas et al., 2000). In cell culture, LTBP-1 is first co-localized 
with fibronectin, and later with fibrillin. In vivo, LTBP-1 and fibrillin-1 colocalize in tendons 
(Isogai et al., 2003). However, LTBP-1 is not an integral part of microfibrils of elastic fibers 
(Isogai et al., 2003). LTBP1 is located in the skin only around hair follicles, while fibrillin-1 
is abundant in human dermis (Isogai et al., 2003). The C-terminal parts of both LTBP-1 and 
LTBP-4 can associate with fibrillin-1. Overexpression of LTBP-1 has been observed in 
pathological conditions, such as IgA nephropathy, chronic C hepatitis, idiopathic pulmonary 
fibrosis, and ovarian carcinoma (Kwak et al., 2005). LTBP-1 knockout mice are fertile and 
lack gross abnormalities. However, they exhibit shortened skull and abrogated surgery-





Figure 3. The domain structures of LTBPs. Modified from Saharinen et al., 1999. 
 
LTBP-2 differs from the other family members in the respect that it does not bind SLC. 
Instead, it has functions in cell adhesion to the matrix, and its importance is underlined by the 
fact that LTBP-2 knockout embryos die between embryonic days 3.5 and 6.5 possibly due to 
disrupted implantation (Shipley et al., 2000). LTBP-2 is expressed in the lung, heart, placenta, 
liver and skeletal muscle. It is associated with elastic fibers. Melanoma cells adhere to LTBP-
2 via β1, α3 and α6 integrins (Vehviläinen et al., 2003). In cell culture, LTBP-2 deposition to 
ECM depends on preformed fibronectin and fibrillin-1 matrices (Vehviläinen et al., 2009). 
LTBP-3 is expressed in the skeletal muscle, heart, prostate, ovaries, testis, and small 
intestine (Penttinen et al., 2002). It exists as two forms, with the longer form containing 
additional calcium binding EGF-repeat in C-terminal domain (Penttinen et al., 2002). LTBP-3 
knockout mice develop cranio-facial abnormalities, kyphosis, osteosclerosis and osteoarthritis 
(Dabovic et al., 2002). 
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LTBP-4 was identified from human heart cDNA library by using 3
rd
 8-Cys repeat 
sequence of LTBP-1 (Saharinen et al., 1998). LTBP-4 has several splice variants, one of 
which lacks the 3
rd
 8-Cys repeat required for binding SLC (Koli et al., 2001; Saharinen et al., 
1998). LTBP-4 is expressed in the aorta, heart, uterus, small intestine, skeletal muscle and 
ovaries (Giltay et al., 1997; Saharinen et al., 1998). LTBP-4 binds to fibronectin via its N-
terminal region, and the disruption of its association to ECM leads to increased TGF-β 
activity (Kantola et al., 2008). LTBP-4 has long and short transcripts, which are regulated by 
two distinct promoters and different expression patterns (Kantola et al., 2010). Thus, LTBP-
4S is expressed in the heart, skeletal muscle, lung and small intestine, while LTBP-4L is 
expressed in the heart, skeletal muscle, and liver (Kantola et al., 2010). LTBP-4 knockout 
mice develop lung emphysema, cardiomyopathy, and colorectal cancer (Sterner-Kock et al., 
2002). Tissues of the knockout mice exhibit defects in elastic fibers, and reduced TGF-β 
signalling (Sterner-Kock et al., 2002).  
 
3.4.3 Activation and signalling of TGF-β  
 
To be able to bind to its receptor, in other words to become activated, TGF-β has to be 
released from LAP. This can occur through chemical alterations of the environment, such as 
heat, acid, and urea treatment, by proteases, such as plasmin, thrombin, BMP1-like 
proteinase, MT1-MMP, calpain, and cathepsin G, by conformation change of LAP induced by 
thrombospondin-1 or integrins, such as αvβ6, αvβ8, and by shear force (Ribeiro et al., 1999; 
Saharinen et al., 1999; Sato et al., 1993; Taipale et al., 1992). The LAP of TGF-β2, however, 
lacks RGD sequence and cannot be activated via integrins (Sheppard, 2005).  
Correct targeting of LLC to ECM is essential for the regulation of TGF-β activation. 
Increased TGF-β activation accounts for the part of symptoms in Marfan syndrome, a disease 
caused by mutation in fibrillin-1 gene (Neptune et al., 2003). Since LTBPs associate with 
fibrillin-1 (Dallas et al., 2000; Kantola et al., 2008), this suggests that disrupted fibrillin 
assembly in Marfan patients prevents LLC targeting to ECM, leading to the pathologic TGF-β 
activation. 
The cleavage of LTBP-1 in its hinge-region for example by mast cell chymase, 
leukocyte elastase, and BMP-1 releases cleaved LLC from ECM, which may be the first step 
in TGF-β activation (Ge and Greenspan, 2006; Taipale et al., 1995). In addition, the secretion 
of active TGF-β into the conditioned medium can be induced by treating the keratinocyte 
cultures with retinoids or vitamin D3, and cancer cells with antiestrogens and glucocorticoids 
(Koli and Keski-Oja, 1993; Saharinen et al., 1999). Coculture of endothelial cells with 
pericytes produces activated TGF-β, which exerts inhibitory effect on endothelial cell 
migration (Antonelli-Orlidge et al., 1989; Sato and Rifkin, 1989). Activation in this coculture 
system occurs at the cell surface and is prevented by inhibitors of plasmin (Sato and Rifkin, 
1989) and antibodies against cation-independent mannose-6-phosphate receptor (CI-MPR) 
and LTBP-1 (Dennis and Rifkin, 1991; Flaumenhaft et al., 1993). 
TGF-β receptors are transmembrane serine/threonine kinases and are divided to type I 
and type II receptors. First active TGF-β binds to type II receptor. The ligand/receptor 
complex is recognized by type I receptor, which binds to type II receptor. The receptor 
complex consists of two type I receptors and two type II receptors bound to TGF-β dimer 
(Massague, 2012). Seven type I and five type II receptors have been identified in man. TGF-β 
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binds to only one type II receptor, TβRII, and three type I receptors, ALK1, ALK2 and 
ALK5. Most of the TGF-β signalling occurs via ALK5, ALK-1 being important for TGF-β 
signalling in endothelial cells. Upon receptor complex activation, type II receptors 
phosphorylate type I receptors, which can then bind to and phosphorylate R-Smads (receptor 
activated Smads). ALK5 binds and phosphorylates Smad2 and -3, while ALK1 activates 
Smad1 and -5. Phosphorylated R-Smads bind to Co-Smad, Smad4, and translocate into the 
nucleus, where they regulate gene expression (Attisano and Wrana, 2002). Inhibitory Smads 
(Smad-6 and -7) counteract the effects of R-Smads. 
 
3.4.4 Functions of TGF-β in melanoma 
 
The importance of TGF-β1 as a strong modulator of the immune system is underlined by the 
profound immune cell infiltration of the tissues in TGF-β1 knockout mice, which die shortly 
after birth (Shull et al., 1992). In cancer, TGF-β1 promotes tumor growth by inhibiting 
immune surveillance. Unlike other cancers, no mutations in TGF-β pathway have been found 
in melanoma (Rodeck et al., 1999). Nevertheless, the production of TGF-β is increased during 
the progression of melanoma (Berking et al., 2001), and, like many other cancers, melanoma 
is resistant to growth-restricting signals of TGF-β (Krasagakis et al., 1999; Rodeck et al., 
1999). TGF-β1 and -3 are expressed by both melanocytes and melanoma cells (Hussein, 
2005), but TGF-β2 is expressed specifically by melanoma cells and is associated with 
melanoma invasion level (Reed et al., 1994). TGF-β may induce melanoma progression by 
upregulating MMP-9, integrins β1 and β3, and by downregulating E-cadherin (Janji et al., 
1999). Further, TGF-β induces melanoma cell adhesion to endothelial cells (Teti et al., 1997). 
TGF-β overexpressing melanoma xenografts produce more stroma, exhibit less apoptosis and 
increased lung metastasis (Berking et al., 2001). These effects are mediated by TGF-β 
stimulation of stromal fibroblasts to produce collagens type VI, XV, XVIII, fibronectin and 
tenascin, which may provide scaffolding for migration of melanoma cells (Berking et al., 
2001).  
 
4. Composition of the skin  
 
Skin is the largest organ of our body. It provides not only mechanical protection, but has 
functions in heat regulation, sensation, excretion from sweat glands, absorption of ultraviolet 
radiation for the synthesis of vitamin D, and anti-microbic surveillance. It consists of upper 
layer, epidermis, and lower layer, dermis, which are separated by basement membrane. 
Epidermis is derived from ectoderm and is composed of stratified squamous keratinized 
keratinocytes. Its thickness is between 0.07 and 0.12 mm, but on the soles it can be as much 
as 1.4 mm. Keratinocytes are constantly renewed through proliferation in the basal layer of 
epidermis, from where older keratinocytes are pushed upwards, differentiate and accumulate 
keratin filaments, lose their nuclei and die (Fuchs, 2008). The life cycle of a keratinocyte lasts 
from 20 to 30 days. Psoriasis is a disease where keratinocyte proliferation is increased (about 
7-fold), leading to patchy lesions, especially on the scalp, knees and elbows. Basal cell 
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carcinoma and squamous cell carcinoma arise from the keratinocytes (Gartner and Hiatt, 
2001). 
Melanocytes reside in the basal layer of epidermis or upper dermis, with their long 
processes extending to the upper layers of epidermis. They are originally derived from the 
neural crest. Tyrosinase produced in these cells is packed to melanosomes by the Golgi 
apparatus. When it is activated by ultraviolet light, tyrosinase catalyzes the reaction of 
transition of tyrosine to melanin. Melanosomes travel to the tip of the process of melanocytes. 
The tip then penetrates into the cytoplasm of a keratinocyte, and becomes pinched off. This 
process is called cytocrine secretion. Within keratinocytes, melanosomes are settled in the 
supranuclear region, protecting nuclear DNA from ultraviolet rays. Eventually, melanin is 
degraded by lysosomes of the keratinocyte. The number of melanocytes ranges from 800 to 
2300/mm
2
 and is almost the same in all races. The darkness of the skin depends in turn on 
tyrosinase activity (Gartner and Hiatt, 2001; Marks and Seabra, 2001). 
Epidermis contains also other cells, such as Merkel cells (acting as mechanoreceptors or 
neuroendocrine cells and derived from neural crest, Halata et al., 2003), and Langerhans cells 
(antigen presenting cells). Unlike melanocytes, which proliferate after exposure to UV 
radiation, Langerhans cells decrease in number in response to UV radiation, which might 
contribute to carcinogenesis.  
The dermis is derived from mesoderm and consists of collagen types I and III, which 
form 85-90% and 10-15% of total skin collagen, respectively, and co-exist in the same fibers 
(Vitellaro-Zuccarello et al., 1992). With aging, collagen fibrils become enzymatically 
degraded, resulting in decreased adhesion of fibroblasts to collagen, and reduced production 
of new collagen type I by fibroblasts (Quan et al., 2012).  
Upper layer of dermis, the papillary dermis, contains thin type I/III collagen fibers and 
elastic fibers. Anchoring fibrils, composed of collagen type VII, bind epidermis to dermis. 
Papillary dermis is rich in cells, such as macrophages, fibroblasts and mast cells. Capillary 
loops of the papillary layer nourish epidermal cells and regulate body temperature. Meissner 
corpuscles of papillary dermis are mechanoreceptors sensitive to light touch and probably act 
also as nociceptors (Widera et al., 2012).  
Reticular dermis is the lower layer of the dermis, which is composed of thick collagen 
type I/III fibers lying parallel to the skin surface, thick elastic fibers which are intermingled 
with collagen fibers, and proteoglycans (Watt and Fujiwara, 2011). Reticular dermis contains 
fewer cells, which include fibroblasts, mast cells, lymphocytes and macrophages. Sweat 
glands, sebaceous glands and hair follicles, though being of epidermal origin, invade the 
dermis and subcutaneous tissue during embryogenesis. Arrector muscles are inserted into the 
hair follicles and contract when the body is exposed to cold, creating “goose bumps”. 
Pacinian receptors which are sensitive to pressure and vibration, and ruffini corpuscles which 
respond to tensile forces, are located also in the reticular dermis. 
The subcutaneous tissue is composed of fat, sweat glands, blood and lymphatic vessels, 
and cutaneous nerves. It protects the skin from the underlying bony prominences. Skin 
ligaments (L. retinacula cutis) extend from the deep fascia to the dermis and prevent the 






5. Matrix metalloproteinases 
 
Matrix metalloproteinases form a family of enzymes closely involved in various pathological 
conditions of the skin, such as psoriasis, atopic dermatitis, as well as skin cancer including 
melanoma (Buommino et al., 2012; Harper et al., 2010; Hofmann et al., 2005). Matrix 
metalloproteinases belong to the metzincin family, which is in turn part of metalloproteinase 
superfamily (Gomis-Ruth, 2003). They were originally discovered in vertebrates as 
collagenolytic enzymes involved in tail resorption during frog metamorphosis (Gross and 
Lapiere, 1962). The term matrix metalloproteinase was introduced at the first international 
MMP conference in Destin, Florida (Brinckerhoff and Matrisian, 2002). MMPs have been 
described in all organisms, from archaebacteria to worms and plants. They function in the 
events such as blastocyst implantation, embryogenesis, tissue remodelling, bone resorption, 
wound healing, and a plethora of pathological conditions. MMPs can degrade all ECM 
proteins. In addition, they cleave cell surface receptors, growth factors, chemokines, and other 
MMPs. The ADAMs (a disintegrin and metalloproteinase) and ADAMTSs (a disintegrin and 
metalloproteinase with thrombospondin motifs) are a related group of zinc-dependent 
transmembrane proteases of metzincin family. They act primarily as sheddases, cleaving the 
ectodomains of cell surface proteins and receptors. Similarly to MMPs, ADAMs are 
upregulated during inflammation, and are implicated in several other pathological conditions, 
including melanoma (Huovila et al., 2005).  
 
5.1 Structures of MMPs 
 
The human MMP family consists of 23 zinc-dependent enzymes (Chernov and Strongin, 
2011), 7 of which are produced with a membrane anchor. Secreted MMPs can be divided into 
collagenases, which cut collagen triple helix generating ¾ and ¼ fragments, gelatinases, 
capable of cleaving denatured collagens, and stromelysins and matrilysins, which can cleave 
various ECM and non-ECM substrates and proteoglycans.  
Starting at the N-terminus, a signal peptide, a propeptide, a catalytic domain, a hinge 
region, and a hemopexin-like (PEX) domain are found in almost all MMPs (Fig. 4). All 
MMPs are synthesized as latent zymogens, and their latency is maintained by an interaction 
of a cysteine-sulphydryl group in the propeptide and the zinc ion of the catalytical domain. 
The N-terminal propeptide prodomain must be cleaved upon their activation (Sternlicht and 
Werb, 2001). 
The membrane-type matrix metalloproteinase family comprises 6 members, four of 
which (MT1-, MT2-, MT3- and MT5-MMPs) have stalk region, transmembrane and cytosolic 
domains (type I transmembrane), while two of them (MT4- and MT6-MMPs) are 
glycophosphotidyl inositol (GPI)-anchored to the cell membrane. ProMMP-23 contains a 
potential membrane spanning region (type II transmembrane) in its N-terminus. The cleavage 
of MMP-23 propeptide both activates it and releases the soluble enzyme from the cell 










Figure 4. Domain structures of MMPs. Modified from Radisky and Radisky, 2010. 
 
 
PEX domain is found in all MMPs except MMP-7, MMP-23, and MMP-26, and is 
essential for the substrate specificity of MMPs. For example, PEX domain is required for 
unwinding collagen type I triple helix by MMP-1, MMP-13 and MT1-MMP (Knäuper et al., 
1997; Manka et al., 2012; Tam et al., 2002), for substrate specificity of MMP-8 (Gioia et al., 
2002), MMP-9 binding to gelatin (Roeb et al., 2002), MMP-2 binding to fibrinogen (Monaco 
et al., 2007), for MT1-MMP homodimerization and MMP-2 activation (Itoh et al., 2001; Lehti 
et al., 2002), for heteromerization of MT1-MMP with CD44, MT1-MMP localization to 
lamellipodia, and MT1-MMP-mediated directional migration (Mori et al., 2002). 
Interestingly, MT1-MMP PEX domain is not necessary for 3D collagen invasion, but is 
required for fibrin invasion (Li et al., 2008). However, MT1-MMP with deleted PEX 
degrades collagen type I less efficiently than wild-type MT1-MMP (Li et al., 2008). MT1-
MMP mutant with the PEX from MT3-MMP, in turn, cannot confer cells with collagenolytic 
activity, but drives cell invasion through fibrin and activates MMP-2 as efficiently as the wild 
type MT1-MMP (Jiang and Pei, 2003; Li et al., 2008). The contrasting results that MT1-MMP 
PEX domain is not required for MMP-2 activation but is necessary for mediating 3D collagen 
invasion have been reported (Wang et al., 2004), which may be due to different 
overexpression systems, cell types and collagen degradation/invasion assays used (Li et al., 
2008). 
Gelatinases (MMP-2 and MMP-9) contain additional fibronectin type II repeats, which 
are required for collagen binding and cleavage (Steffensen et al., 1995).  
The cytosolic domain of MT1-MMP is required for the enzyme targeting to the cell 
membrane and invadopodia, and for clathrin-mediated endocytosis (Jiang et al., 2001; Lehti et 
al., 2000; Nakahara et al., 1997), but not for proMMP-2 activation or collagen invasion 
(Hotary et al., 2003; Lehti et al., 2000). It is further required for the MT1-MMP-induced ERK 
phosphorylation and cell migration (Gingras et al., 2001; Gingras and Beliveau, 2010). The 
generation of proteolytically active soluble MT1-MMP by cleaving its ectodomain close to 
the cell membrane has been reported (Toth et al., 2005), but the anchoring of MT1-MMP to 
the cell membrane is essential for tightly regulated pericellular proteolysis and collagen type I 
invasion (Hotary et al., 2000). 
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5.2 Membrane-type matrix metalloproteinases 
 
MT1-MMP is a prototype of the MT-MMP family, widely expressed in connective tissue, 
vasculature, bones, lung, liver, kidneys, and placenta (Apte et al., 1997; Holmbeck et al., 
1999; Shofuda et al., 1997; Takino et al., 1995). It is essential for bone and connective tissue 
homeostasis, collagen type I turnover, angiogenesis, wound healing, and tooth development 
(Hiraoka et al., 1998; Holmbeck et al., 1999; Itoh and Seiki, 2006; Okada et al., 1997). The 
MT1-MMP knockout mice are born small, with fibrosis of soft connective tissue, delayed 
bone ossification, defects in the vasculature, and they die soon after birth (Holmbeck et al., 
1999; Zhou et al., 2000). Like other MMPs, MT1-MMP is synthesized as a zymogen, and its 
N-terminal propeptide needs to be cleaved for activation (Nagase, 1997). This takes place 
mainly inside the Golgi apparatus by furin and other proprotein convertases (Mazzone et al., 
2004; Sato et al., 1996; Yana and Weiss, 2000). In addition, plasmin can cleave recombinant 
soluble MT1-MMP propeptide (Okumura et al., 1997), but not the membrane anchored wild-
type MT1-MMP (Monea et al., 2002). MT1-MMP is upregulated in tumor and stromal cells 
of many cancers, such as breast, prostate, colon, gastric, cervical, pancreatic cancer, 
osteosarcoma, head and neck carcinoma, melanoma, and is often associated with cancer 
progression and poor prognosis (Iacobuzio-Donahue et al., 2002; Jiang et al., 2006; Mimori et 
al., 2008; Nomura et al., 1995; Okada et al., 1995; Riker et al., 2008; Uchibori et al., 2006; 
Zhai et al., 2005).  
MT2-MMP is also expressed in some cancer cells, and has been found to prevent 
apoptosis of tumor cells (Abraham et al., 2005). The expression of MT2-MMP in tumor cells 
can be elevated in response to tumor hypoxia via HIF-1α, which can serve as a mechanism by 
which tumor cells evade apoptosis triggered by hypoxia (Zhu et al., 2011). 
MT3-MMP is expressed in microglial cells of both white and grey matter of adult brain, 
in heart, lung, placenta, bone, and smooth muscle cells (Shi et al., 2008; Shofuda et al., 1997; 
Takino et al., 1995; Yoshiyama et al., 1998). MT3-MMP is expressed in corneal epithelium 
during development, where it cleaves CD44 and modulates ECM to allow effective invasion 
of neural crest cells (Huh et al., 2007). MT3-MMP is also expressed in fetal brain, suggesting 
that it might contribute to brain development (Shofuda et al., 1997). Consistently, the loss of 
MT3-MMP gene as a result of chromosomal translocation has been associated with human 
autism (Borg et al., 2002). MT3-MMP is also overexpressed in brain malignancies (Nakada et 
al., 1999; Xia et al., 2009), and malignancies derived from neural crest or neuroectoderm, 
such as melanoma, medulloblastoma, and neuroblastoma (www.genesapiens.org, Kilpinen et 
al., 2008). In addition, MT3-MMP is expressed in hepatocellular carcinoma, and a bladder 
cancer cell line (Arai et al., 2007; Takino et al., 1995; Xu et al., 2008). MT3-MMP knockout 
mice are fertile, but display slightly retarded skeletal growth (Shi et al., 2008). MT1-
MMP/MT3-MMP double knockout mice have more severe skeletal defects than MT1-MMP 
knockout mice, suggesting that MT3-MMP may also participate in skeletal development (Shi 
et al., 2008). The alternative splicing of MT3-MMP mRNA produces its soluble form 
expressed in human ovary (Matsumoto et al., 1997). Instead of transmembrane and 
intracellular domains, this form possesses a novel sequence of 50 amino acids at its C-
terminus. Soluble MT3-MMP can activate MMP-2 and cleave collagen type III and 
fibronectin (Matsumoto et al., 1997). 
MT4-MMP is expressed in the brain, colon, ovary, testis, and macrophages (English et 
al., 2000). It has been reported to promote breast cancer metastasis (Chabottaux et al., 2006). 
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The purified catalytic domain of MT4-MMP can activate MMP-2 (Wang et al., 1999), but the 
overexpressed mouse MT4-MMP does not cleave proMMP2 to its activated form (English et 
al., 2000). MT4-MMP knockout mice appear normal, but have diminished thirst (Srichai et 
al., 2011). 
MT5-MMP is expressed in brain, kidney, pancreas and lung. Its expression is further 
upregulated in brain tumors (Llano et al., 1999). 
MT6-MMP is expressed in the lung, spleen, and neutrophils, and it facilitates 
transendothelial migration of neutrophils (Nie and Pei, 2003; Pei, 1999). MT6-MMP is also 
overexpressed in the brain, urothelial, prostate and colon tumors (Sohail et al., 2008; Sun et 
al., 2007; Velasco et al., 2000).  
 
5.2.1 Substrates of MT-MMPs 
 
The substrate range of the MMP family members is extremely wide. They can cleave virtually 
any ECM component and many other extracellular and cell surface proteins (Table 2). Since 
MT-MMPs are membrane-anchored, they engage in pericellular proteolysis, a process where 
proteolytic activity is concentrated at the cell surface and especially at the invading structures 
of the cell. By cleaving pericellular native collagen type I, MT1-MMP and MT2-MMP endow 
the cells with the ability to invade through collagen rich tissues (Sabeh et al., 2004). In 
addition, MT1-MMP cleaves collagen type II, III, IV, laminin, fibronectin, tenascin, fibrin, 
and many other ECM proteins (Sternlicht and Werb, 2001, Table 2). MT3-MMP can cleave 
e.g. collagen type III, IV, fibronectin, fibrin, laminin, and vitronectin (Table 2). 
The first proteolytic activity to be described for MT1-MMP was cleaving and activating 
proMMP-2 (Sato et al., 1994). MT1-, MT2-, MT3-, MT5- and, to some extent, MT6-MMP 
can cleave the 72 kDa proMMP-2 to its 64 kDa intermediate form, which is then 
autocatalytically cleaved to the active 62 kDa form (Atkinson et al., 1995; English et al., 
2000; Nie and Pei, 2003). Tissue inhibitor of metalloproteinases 2 (TIMP-2) is required for 
MMP-2 activation by MT1-MMP. The N-terminal domain of TIMP-2 binds to the catalytic 
domain of MT1-MMP, and its C-terminal domain binds to the PEX domain of proMMP-2 
(Butler et al., 1998; Strongin et al., 1995). Homotypic oligomerization of MT1-MMP via PEX 
and cytoplasmic domains facilitates MMP-2 activation (Itoh et al., 2001; Lehti et al., 2002). 
Plasmin can also activate MMP-2 in the presence of MT1-MMP, independently of MT1-
MMP proteolytic activity (Monea et al., 2002).  
MT1-MMP can cleave a number of cell surface proteins and receptors (Tomari et al., 
2009, Table 2). For example, it cleaves CD44, ADAM9, syndecan-1, αv, α3, and α5 integrin 
subunits, among others (Endo et al., 2003; Kajita et al., 2001; Ratnikov et al., 2002; Chan et 
al., 2012). MT3-MMP has also been described to cleave several cell surface proteins, such as 
the amyloid precursor protein (APP), CD44, endogenous Nogo-66 receptor 1 (NgR1), tissue 
transglutaminase (tTg), and syndecan-1, but the biological functions of these cleavages have 
largely remained unknown (Ahmad et al., 2006; Belkin et al., 2001; Endo et al., 2003; Ferraro 












Col I, II, III, VII, VIII, X, XI, 
gelatin, tenascin, nidogen, MBP, 
aggrecan, perlecan, IGFBP-2, -3, 
fibronectin, laminin, vitronectin, 
fibrin 
ProMMP-1, -2, casein, α2M, A1AT, 
α1AC, proTNFα, CTGF, dickkopf-1, 
DJ-1, neuron specific enolase, 




Col I, II, III, gelatin, aggrecan, 
tenascin 
ProMMP-8, α2M, A1AT, DJ-1, 
iduronate-2-sulfatase, neuron specific 




Col I, II, III, VI, IX, X, XIV, 
gelatin, aggrecan, tenascin, 
osteonectin, fibrin, fibrillin, 
fibronectin 









Gelatin, elastin, fibronectin, Col I, 
IV, V, VII, X, XI, laminin, 
aggrecan, vitronectin, decorin, 
MBP, IGFBP-3/5, nidogen, 
fibrillin, osteonectin, tenascin, 
IGFBP-4, -6, osteopontin, fibrin 
ProMMP-1, -2, -13, plasminogen, 
casein, α2M, A1AT, α1AC, proTNFα, 
proTGFβ2, proIL-1β, MCP3, FGFr1, 
APOE, CTGF, cystatin C, DJ-1, 
follistatin-like-1, -3, CX3CL-1, 
galectin-1, -3, HSP-90α, iduronate-2-
sulfatase, neuron specific enolase, 
Niemann-Pick C2, pentraxin-3, 
pleiotrophin, PCPE, progranulins, 




Gelatin, Col IV, V, VII, XI, XIV, 
XVII, elastin, fibrillin, 
fibronectin, aggrecan, fibrin, 
MBP, decorin, laminin, 
osteonectin, vitronectin, IGFBP-4 
Plasminogen, casein, α2M, A1AT, 
proTNFα, proTGFβ2, proIL-1β, APP, 
integrin β2, dickkopf-1, DJ-1, 
follistatin-like-3, LIF, neuron specific 
enolase, nexin-1, Niemann-Pick C2, 
pentraxin-3, progranulins, Ym-1, 
galectin-3, C1q 
 




Fibronectin, laminin, gelatin, Col 
III, IV, V, VII, IX, X, XI, elastin, 
decorin, nidogen, perlecan, 
aggrecan, tenascin, fibrin, fibrillin, 
vitronectin, IGFBP-3 
ProMMP-1, -3, -7, -8, -9, -13, 
plasminogen, casein, α2M, A1AT, 
α1AC, proTNFα, E-cadherin, proIL-
1β, VEGF-A, proHB-EGF, CTGF, C1q 
MMP-10 
(stromelysin-2) 
Fibronectin, laminin, gelatin, COL 
II, III, IV, V, IX, X, XI, decorin, 
elastin, nidogen, fibrin, fibrillin, 
tenascin, vitronectin, aggrecan 
ProMMP-1, -8, -10, casein 
MMP-11 
(stromelysin-3) 
Laminin, fibronectin, aggrecan, 
IGFBP-1 
α2M, A1AT, galectin-1 
MMP-7 (matrilysin-
1) 
Fibronectin, laminin, Col IV, 
gelatin, aggrecan, decorin, nidogen, 
elastin, fibrillin, laminin, MBP, 
ProMMP-2, -7, casein, A1AT, pro α-
defensin, FasL, integrin β4, E-cadherin, 
plasminogen, proTNFα, APOE, 
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osteonectin, tenascin, vitronectin syndecan-1 
MMP-26 
(matrilysin-2) 
Col IV, gelatin, fibronectin, fibrin Pro-MMP9, casein, A1AT 
MMP-12 Col IV, elastin, fibronectin, fibrin, 
laminin, nidogen, fibrillin, 
vitronectin 
Plasminogen, casein, α2M, A1AT, 
proTNFα 
MMP-19 Col IV, gelatin, fibronectin, 
tenascin, aggrecan, COMP 
Casein 
MMP-20 Amelogenin, aggrecan, COMP  
MMP-21 ND  
MMP-23 Gelatin  
MMP-27 ND  
MMP-28 (epilysin) ND Casein 
 




Col I, II, III, IV, gelatin, 
fibronectin, laminin-1, -5, 
vitronectin, aggrecan, tenascin, 
nidogen, perlecan, fibrin, fibrillin, 
laminin, Cyr61 
ProMMP-2, -13, α2M, A1AT, CD44, 
CXCL12, proTNFα, tTg, integrin αv, 
APOE, death receptor 6, dickkopf-1, 
DJ-1, follistatin-like-3, galectin-1, 
HSP-90α, iduronate-2-sulfatase, IL-8, 
neuron specific enolase, Niemann-Pick 
C2, pentraxin-3, progranulins, SLPI, 
thrombospondin-1, EMMPRIN, APP, 




Col I, IV, gelatin, fibronectin, 
laminin-1, vitronectin, aggrecan, 




Col III, IV, gelatin, casein, 
fibronectin, laminin-1, vitronectin, 
aggrecan, fibrin 




Gelatin, fibrillin, fibronectin proTNFα, ADAMTS4 
MMP-24 (MT5-
MMP) 
Heparan and chondroitin sulfate 








Table 2. The substrates of MMPs. Modified from Ahmad et al., 2006; Belkin et al., 2001; 
Chan et al., 2012; Endo et al., 2003; Ferraro et al., 2011; Golubkov and Strongin, 2012; 
Koziol et al., 2012; McCawley and Matrisian, 2001; Morrison et al., 2009; Patwari et al., 
2005; Prudova et al., 2010; Shiryaev et al., 2009; Sternlicht and Werb, 2001. 
Abbreviations: α1AC, alpha1 antichymotrypsin; α2M, alpha2 macroglobulin; α2-MRAP, alpha2 macroglobulin 
associated protein; A1AT, α1-antitrypsin; APOE, apolipoprotein E; APP, amyloid β A4 protein; C1q, 
complement C1q; Col, collagen; COMP, cartilage oligomeric matrix protein; CTGF, connective tissue growth 
factor; Cyr61, cystein-rich 61; EGF, epidermal growth factor; EMMPRIN, extracellular matrix metalloproteinase 
inducer; HSP-90α, heat shock protein 90 kDa alpha; IGFBP, insulin-like growth factor binding protein; IL, 
interleukin; MBP, myelin basic protein; ND, not determined; NgR1, Nogo-66 receptor-1; PAI, plasminogen 
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activator inhibitor; PCPE, procollagen C-endopeptidase enhancer 1; proHB-EGF, proheparin- binding EGF-like 
growth factor; PTK-7, protein-tyrosine pseudokinase 7; Sem3C, semaphorin 3C; SLPI, secretory leukocyte 
peptidase inhibitor;  tTg, tissue transglutaminase 
 
5.2.2 Regulation of MT-MMP activity 
 
The activity of MT-MMPs is regulated mainly by posttranslational modifications/processes, 
such as autocatalytic cleavage and endocytosis, and inhibition by endogenous inhibitors. In 
addition, some transcriptional regulation occurs. Many MMP promoters contain elements 
interacting with such transcription factors as AP-1, NF-kB, and PEA3, suggesting coordinated 
transcription in response to growth factors or cytokines (Yan and Boyd, 2007). Unlike most 
MMPs, the promoters of both MMP-2 and MT1-MMP lack a conserved TATA box and AP-1 
binding sites (Huhtala et al., 1990; Lohi et al., 2000). MT1-MMP promoter contains 
overlapping binding sites for transcription factors Sp1 and Egr-1, while MMP-2 promoter 
contains binding site only for SP-1 (Haas and Madri, 1999). AP-2 inhibits the transcription of 
MMP-2 and MMP-9 (Davidson et al., 2004; Frisch and Morisaki, 1990). Wnt/β-catenin 
pathway upregulates MT1-MMP via TCF transcription factor in colon carcinoma cells 
(Hlubek et al., 2004). In melanoma, β-catenin in turn upregulates the microphthalmia-
associated transcription factor (MITF), which suppresses MT1-MMP expression, with 
subsequent inhibition of melanoma cell invasion in collagen (Arozarena et al., 2011). β-
catenin upregulates also MT3-MMP in gastric cancer through unknown transcription factor 
(Lowy et al., 2006).  
MT1-MMP transcription can be triggered by PMA, concavalin A and TNF-alpha 
(Lewalle et al., 1995; Migita et al., 1996), but not by bFGF or TGF-β1 (Lohi et al., 1996). 
Granulocyte-macrophage colony stimulating factor (GM-CSF) upregulates MT1-MMP 
mRNA via MEK in endothelial cell spheroids (Krubasik et al., 2008). Homeobox D10 inhibits 
MT1-MMP expression in endothelial cells (Myers et al., 2002). miR-10b in turn inhibits 
HOXD10, thus inducing MT1-MMP activity and glioma invasion (Sun et al., 2011). MT3-
MMP can also be inhibited by microRNAs, namely miR-146a and miR-146b, leading to 
reduced cell motility of cultured glioma, colon cancer, and pancreatic cancer cells (Astarci et 
al., 2012; Lin et al., 2011; Xia et al., 2009). The translation of MT3-MMP is, in addition, 
tightly regulated by the formation of G-quadruplex in the 5’UTR region of its mRNA, which 
inhibits gene translation by more than half (Morris and Basu, 2009).  
EMMPRIN, a member of the immunoglobulin family, induces MT1-MMP mRNA 
expression, the invasion of breast epithelial and carcinoma cells, and the formation of 
invadopodia, where MT1-MMP colocalizes with EMMPRIN (Grass et al., 2012). Tumor cell 
EMMPRIN is further cleaved by MT1-MMP, and its shed fragment can induce MMP-2 
expression in fibroblasts (Egawa et al., 2006). 
Interestingly, ECM itself and its mechanical properties regulate the transcription of 
MT1-MMP. Cultivation of cells inside 3D collagen type I but not on thin collagen or plastic 
induces MT1-MMP transcription and MMP-2 activation through the induction of MAPK and 
expression of Egr-1 transcription factor mRNA (Azzam and Thompson, 1992; Boyd et al., 
2005; Haas et al., 1998; Montesano et al., 1999). This effect is mediated by integrin α2β1 and 
α3β1 clustering upon binding to collagen, which leads to Src phosphorylation and Egr-1 
upregulation (Barbolina et al., 2007). Integrin clustering induces the localization of MT1-
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MMP to the integrin complexes on the cell surface, allowing specific targeting of pericellular 
proteolysis to the invading edge of the cell (Ellerbroek et al., 2001; Munshi and Stack, 2006; 
Wolf et al., 2003).  
Posttranslational regulation of MT-MMP activity involves autocatalytic cleavage, 
endocytosis and degradation, phosphorylation, and inhibition of activity by endogenous tissue 
inhibitors of metalloproteinases (TIMPs). MT1-MMP activity correlates with accumulation of 
its inactive autocatalytic 43-45 kDa fragments (Ellerbroek et al., 2001; Lehti et al., 1998; 
Lehti et al., 2000; Lohi et al., 1996). This cleavage occurs mainly in trans by an adjacent 
molecule of MT1-MMP. In addition, the induction of the MT1-MMP cleavage to its 44 and 
37 kDa fragments by incubation with active MMP2, MMP13 and soluble MT1-MMP has 
been described (Stanton et al., 1998). The 44 kDa truncated fragment of MT1-MMP can 
prevent its collagenolytic activity, providing a feedback mechanism for regulation of MT1-
MMP activity (Tam et al., 2002). 
Internalization of MT1-MMP is another mechanism to regulate the net amount of the 
active enzyme at the cell surface. It occurs via clathrin or caveolae-dependent endocytosis, for 
example in response to concavalin A treatment (Annabi et al., 2001; Jiang et al., 2001; Uekita 
et al., 2001). Internalized MT1-MMP may be targeted for lysosomal degradation, or recycled 
back to the cell surface (Remacle et al., 2003). The internalization-defective mutant MT1-
MMP does not promote cell invasion, emphasizing the importance of MT1-MMP endocytosis 
for continuous recycling of the active enzyme to the invading cell edge during cell invasion 
(McAllister et al., 1994). Collagen type I, fibronectin, and fibrinogen inhibit MT1-MMP 
internalization in endothelial cells, increasing its cell surface expression in cell-cell contacts, 
where it colocalizes with β1 integrin (Galvez et al., 2002). MT1-MMP trafficking to the 
invadopodia via Rab8- and VAMP-7-dependent exocytosis is essential for collagen invasion 
ability of the cells (Bravo-Cordero et al., 2007; Steffen et al., 2008). 
MT1-MMP activity is regulated also by the Src dependent tyrosine-573 phosphorylation 
of its C-cytoplasmic domain (Nyalendo et al., 2007; Nyalendo et al., 2008). Phosphorylation 
defective mutant accumulates on the cell surface, leading to epithelial-to-mesenchymal 
transition and enhanced collagen invasion of ovarian carcinoma cells (Moss et al., 2009). In 
addition, growth factor receptors regulate MT1-MMP activity. EGFR activation by EGF leads 
to increased MT1-MMP mRNA expression, MT1-MMP phosphorylation, and internalization 
(Moss et al., 2009; Van Meter et al., 2004). Fibroblast growth factor receptor-4 (FGFR4) 
R388 polymorphism induces MT1-MMP phosphorylation and decreases its lysosomal 
degradation, leading to enhanced tumor cell invasion (Sugiyama et al., 2010a; Sugiyama et 
al., 2010b). 
 
5.2.3 Tissue inhibitors of metalloproteinases 
 
Endogenous tissue inhibitors of metalloproteinases (TIMPs) are secreted proteins which 
inhibit MMP activity by non-covalent binding to their catalytically active sites (Baker et al., 
2002). Four different TIMPs have been described in man (Table 3). They are composed of N-
terminal domains, and smaller C-terminal domains, each domain being stabilized by three 
disulfide bonds. N-terminal domain of TIMPs binds to the catalytical sites of MMPs even in 
the absence of their C-terminal domains (Baker et al., 2002). However, C-terminal domain of 
TIMP-2 is essential for the ternary complex formation during MMP-2 activation, as it binds to 
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C-terminal domain of proMMP-2 (Butler et al., 1998; Strongin et al., 1995). In addition, the 
C-terminal domain of TIMP-3 mediates its tight association with ECM (Brew et al., 2000). 
TIMPs exhibit different selectivity towards MMPs and ADAMs (Table 3). Both pro- and 
antitumorigenic effects have been described for TIMPs (Baker et al., 2002). TIMP-2, -3, and -
4 inhibit endothelial tube formation. TIMP-1, -2, and -3 knockout mice are viable and fertile. 
Female TIMP-1 knockout mice have shorter reproductive period (Nothnick, 2001). TIMP-2 
knockout mice appear normal, despite perturbed proMMP-2 activation in the tissues (Caterina 
et al., 2000). This is consistent with almost normal phenotype of MMP-2 deficient mice, 
which exhibit only slight growth reduction (Itoh et al., 1997). TIMP-3 knockout mice develop 
emphysema-like condition starting from two weeks after birth, which correlates with 
increased collagen degradation in their lungs (Leco et al., 2001). 
 
 




      
TIMP-1 28 kDa Soluble Secreted MMPs, 
MT4-MMP, 
MT6-MMP 
ADAM10 TGF-β, bFGF, EGF, 
TNF-α, PDGF, IL-1, 
IL-6, PMA, retinoic 
acid, progesterone, 
oncostatin M 








ECM Secreted MMPs, 
MT-MMPs 
ADAM10, -










Table 3. Tissue inhibitors of metalloproteinases. Modified from Amour et al., 2000; Baker 
et al., 2002; Henriet et al., 1999; Will et al., 1996. 
 
6. Tumor cell invasion 
 
6.1 Types of invasion 
 
Cell migration and invasion are required for various physiological processes, e.g. gastrulation, 
neural crest migration, immune cell surveillance, wound closure, and angiogenesis. In cancer, 
the ability of tumor cells to invade confers them with the lethal metastatic potential. Tumor 
cells can use interchangeable methods to invade across interstitial tissues depending on the 
microenvironment (Alexander et al., 2008). Cell invasion is divided to single cell and 
collective invasion, and single cell invasion can be further classified to amoeboid and 
mesenchymal-type invasion (Fig. 5, Friedl, 2004).  
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In single cell invasion the contacts between the invading cells are lost. Amoeboid 
invasion received its name from the invasive phenotype of amoeba Dictyostelium discoideum. 
Its fast movement is characterised by bleb-like protrusions, weak non-integrin interactions 
with surrounding ECM, and the lack of MMP-dependent ECM degradation (Friedl, 2004). In 
man, leukocytes and some tumor cells engage in amoeboid movement, whereby the cells 
squeeze between the fibers in the pre-existing spaces of the ECM. Protease-independent 
amoeboid invasion is possible only when matrix pore size and rigidity permits cell squeezing 
through the pores. This requires the ability to modify cell shape, and to push the surrounding 
ECM to displace its fibers instead of degrading them (Wolf and Friedl, 2011). Amoeboid 
invasion is fast, 2-25 μm/min (Brabek et al., 2010). Small GTPases are closely involved in the 
mediating signals from the ECM to cytoskeleton, a process required for the cell morphology 
changes during different types of invasion. Thus, RhoA activation is linked to amoeboid type 
invasion, but in 2D environment it mediates stress fiber formation and cell spreading (Friedl, 
2004). In amoeboid invasion, RhoA induces cortical actin polymerization, generating cortical 
tension, stiffness and roundish cell morphology (Friedl, 2004). 
 
 
             
 
 
Figure 5. Types of invasion. Modified from Friedl, 2004. 
 
 
Fibroblasts and most tumor cells engage in slower (0.1-2 μm/min) mesenchymal-type 
movement, where the cells are elongated, have invadopodia/filopodia, integrin-mediated 
adhesions to the ECM, and MMP-dependent matrix degradation activity (Friedl, 2004). This 
type of invasion is often associated with epithelial-to-mesenchymal transition (EMT), where 
epithelial cells downregulate proteins associated with epithelial phenotype, such as E-
cadherin, upregulate mesenchymal markers, such as N-cadherin and vimentin, lose their cell-
cell contacts, and move in a single cell manner. Mesenchymal invasion involves tentatively 
five different steps. First, cell polarization to cell front and rear occurs, which enables 
invadopodia formation at the invading edge (step 1). At the cell front membrane protrusions 
attach to the ECM via focal adhesions, mediated by integrins (step 2), where MT1-MMP, 
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urokinase-type plasmin activator (uPA) and its receptor (uPAR) are also recruited for 
initiation of pericellular proteolysis (step 3, Belkin et al., 2001; Wei et al., 1996; Wolf et al., 
2007). Then, myosin II binds to actin filaments and generates actomyosin contraction (step 4). 
The posterior cell body loses its focal contacts with the ECM, and the trailing tail of the cell 
moves forward (step 5, Friedl and Wolf, 2003; Lauffenburger and Horwitz, 1996). Small 
GTPases Rac1 and Cdc42 are activated during mesenchymal type invasion. They induce 
lamellipodia and filopodia formation, actin assembly, and cell elongation (Friedl, 2004). 
Tumor cells can shift their motility mode between mesenchymal and amoeboid types, called 
mesenchymal-amoeboid transition (MAT), for example when MMP activity is reduced by 
inhibitors (Friedl, 2004; Wolf et al., 2003).  
Recently it has been reported that when cells are confined to move through 3 μm 
channels, they do not use actin polymerization, actomyosin contraction, or small GTPases. 
Instead, this type of movement depends on microtubule polymerization (Balzer et al., 2012). 
Collective invasion has been noticed in the histopathological sections of various human 
cancers, such as melanoma and breast cancer (Friedl et al., 2012; Silye et al., 1998). Vascular 
sprouting can also be considered as an example of collective invasion. In this type of 
movement, multicellular polarization occurs with the leading edge acquiring mesenchymal-
type phenotype with MMP-activity, integrin-dependent ECM adhesion, and invadopodia 
formation, while the cells in the stalk region retain their epithelial-like phenotype and cell-cell 
contacts. Cell-cell contacts are mediated by adhesion junction proteins, such as cadherins, by 
integrins, and by other cell-cell contact proteins, such as L1CAM (Friedl and Gilmour, 2009). 
The invasion type used by tumor cells is dictated by microenvironment. For example, in loose 
connective tissue, HT-1080 cells invade mainly as single cells, whereas in areas with pre-
existing structures, such as collagen fibers, muscles and lymphatic vessels, HT-1080 cells 
engage in collective invasion moving along these structures (Alexander et al., 2008). 
 
6.2 Three-dimensional (3D) matrix models for studies of cell invasion 
 
Cell signalling and expression of adhesion receptors is different in 2D and 3D systems 
(Cukierman et al., 2002). Therefore, 3D models recapitulate better in vivo environment than 
2D migration assays. Both single cell invasion and collective invasion can be analyzed using 
3D models (Friedl and Gilmour, 2009). Interstitial tissue features which affect tumor invasion 
include molecular composition, fiber density, assembly and cross-linking, pore size, stiffness, 
and liner vs. non-linear elasticity (Petrie et al., 2012; Wolf and Friedl, 2011). In vivo, 
connective tissues are rather heterogeneous, with loose and dense areas, gaps, and fiber 
bundles of various thicknesses (Wolf et al., 2009). The most common 3D models which 
mimic some of these features and can be used for cell invasion studies in vitro are the 
hydrogels of collagen type I, fibrin, and a basement membrane analogue Matrigel. The other 
ECM components, such as fibronectin, vitronectin, hyaluronan, laminin, or stromal cells, such 
as fibroblasts, may be added to the hydrogels (Wolf et al., 2009).  
Collagen type I remains soluble after extraction by acidic pH, and needs to be 
neutralized for polymerization to occur. Acid-extracted collagen contains nonhelical 
telopeptides at the N- and C–terminal ends, which covalently crosslink collagen molecules 
together (Sabeh et al., 2009). It is rapidly polymerized upon neutralization, with the eventual 
pore size of 1-2 μm. Pepsin-extracted collagen lacks telopeptides and polymerizes more 
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slowly, with the pore size of 3-5 μm (Wolf et al., 2009). However, Demou et al. (2005) 
reported that the pore size of pepsin-treated collagen is smaller than that of telopeptide-intact 
collagen, suggesting that eventual pore size depends also on the experimental conditions 
(Demou et al., 2005). Matrigel is the trade name for a basement membrane analogue extracted 
from Engelbreth-Holm-Swarm (EHS) mouse sarcoma tumors. It consists mainly of laminin, 
collagen type IV, heparan sulfate proteoglycan and nidogen. Matrigel, however, differs from 
in vivo basement membranes, since its components are much less cross-linked. Subsequently, 
the invasion through Matrigel, unlike the invasion through in vivo basement membrane, does 
not require MMP activity (Hotary et al., 2006; Sodek et al., 2008).  
The composition of 3D collagen gels, the degree of collagen crosslinking, and pore size 
affect the speed of the invading cells, dictates the requirement of MT-MMPs in cell invasion, 
and determines whether the cells can invade in the hydrogel in amoeboid fashion without 
matrix degradation (Sabeh et al., 2009; Wolf et al., 2009). For the cell to move through a 
certain pore without proteolytic degradation, the diameter of the pore must be bigger than 
what the cell nucleus can fit by deformation. The nucleus is the most rigid organelle of the 
cell, being a rate-limiting feature in amoeboid migration (Sabeh et al., 2009; Wolf and Friedl, 
2009). The diameter of the cell nucleus is usually between 5 and 15 μm, while pore size in 
vivo can range from less than 1 μm in the basement membrane to 30 μm in the loose 
connective tissue (Friedl et al., 2011). Myosin II, an ATP-dependent motor protein required 
for actin filament contraction, is required for nucleus deformation during cell migration 
through narrow spaces, since myosin II silenced glioma cells cannot migrate through the 
pores smaller than their nuclear diameters (Beadle et al., 2008). In 3D collagen hydrogels, the 
mechanistic properties of the formed collagen depend, in addition to collagen concentration, 
on the experimental conditions during collagen polymerization. Thus, pH and the temperature 
of collagen solution during polymerization inversely correlate with the eventual collagen fiber 
diameter and pore size of the hydrogel (Raub et al., 2007; Raub et al., 2008; Wolf et al., 
2009).  
Further, chicken chorioallantoic membrane (CAM) is widely used to mimic tumor cell 
microenvironment. It is composed of a chorionic epithelium of ectodermal origin, an 
intermediate mesenchyme, and an endodermal allantoic epithelium. Both epithelium layers 
are separated from the mesenchyme by BM (Li et al., 2008; Ota et al., 2009). In addition, 
organotypic models have been introduced to better mimic in vivo tumor stroma which, in 
addition to ECM proteins, contains various non-malignant cells (Jenei et al., 2011). In human 
leiomyoma organotypic model, tumor cells are cultured atop the disks of myoma tissues, 
which are composed of stromal ECM proteins, fibroblasts, endothelial and inflammatory cells 
(Nurmenniemi et al., 2009). The invasion of myoma tissue by tumor cells is suitable for 
studying MMP functions in tumor invasion since it is MMP-dependent. In addition, mouse 
tissue explants, for example from mouse ears, can be used to study cell invasion (Petrie et al., 
2012). 
 
6.3 MT-MMPs in tumor cell invasion 
 
MT1-MMP is required for tumor cell invasion through 3D native cross-linked type I collagen 
or CAM membrane. Despite the fact that several secreted proteases can cleave collagen type 
I, only membrane-tethered enzymes can promote cell movement through this type of collagen 
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(Sabeh et al., 2004). This may be due to the requirement of targeted pericellular proteolysis at 
the invading edge, or the importance of physical interactions with signalling receptors 
mediated by C-terminal domain of MT-MMPs. In addition, cell surface localization of MT-
MMPs can activate intracellular signalling which promote cell migratory functions. Indeed, 
the activation of ERK signalling by MT1-MMP promotes cell invasion in Matrigel (Gingras 
et al., 2001). MT2-MMP can also drive tumor cell invasion through collagen type I and CAM. 
MT1-, MT2- and MT3-MMP, in turn, can each mediate cell invasion through basement 
membrane and fibrin (Hotary et al., 2006; Hotary et al., 2002). Epithelial-to-mesenchymal 
transition –like changes are often seen in the invading front of the carcinomas. The process is 
regulated by Snail, Slug and Twist transcription factors. Snail-1 induces MT1-MMP and 
MT2-MMP expression, with subsequent induction of CAM invasion (Ota et al., 2009).  
MT1-MMP is recruited to focal adhesions, where it colocalizes with β1 integrin (Wolf 
et al., 2007). Further, MT1-MMP accumulates in invadopodia, where it colocalizes with 
cortactin (Artym et al., 2006; Poincloux et al., 2009). MT1-MMP promotes cell motility also 
by cleaving hyaluronan receptor CD44, which is widely expressed in tumor cells, cell surface 
proteoglycan syndecan-1, and several integrins (Kajita et al., 2001; Endo et al., 2003). Small 
GTPase Rac1 induces MT1-MMP expression and collagen invasion (Itoh et al., 2001; Zhuge 
and Xu, 2001). Thus, MT1-MMP promotes tumor invasion by several mechanisms, including 
ECM matrix degradation, activation of intracellular signalling cascades, regulating 
invadopodia formation, activation of other MMPs, and the cleavage of cell surface proteins, 
which are involved in cell invasion (Fig. 6). Although the expression of the other MT-MMPs 




            
 
 
Figure 6. The functions of MT1-MMP which promote cell invasion. Modified from Itoh 
and Seiki, 2006, Sugiyama et al., 2010a.  
 
40 
7. Tumor microenvironment 
 
Solid tumors are increasingly considered to be not just a mass of transformed cells, but new 
kind of complex organs with interstitial tissue and non-malignant cells which affect tumor 
progression (Hanahan and Weinberg, 2011). The tumor microenvironment consists of ECM, 
growth factors, cytokines, non-malignant cells, blood and lymphatic vessels, nutrients, and 
oxygen (Postovit et al., 2006). Hypoxia can promote both malignant transformation and tumor 
growth by upregulating several signalling pathways, such as HIF-1α (Bedogni et al., 2005; 
Harris, 2002). Interestingly, ECM conditioned by metastatic melanoma cells induces 
malignant transformation of normal melanocytes (Seftor et al., 2005). Furthermore, exposing 
melanoma cells to the embryonic environment (e.g. by injecting them into the chick embryo) 
can reprogram melanoma cells to more benign differentiated phenotype (Kulesa et al., 2006; 
Postovit et al., 2006). 
 
7.1 Tumor ECM 
 
The physical properties of ECM, such as stiffness, porosity, elasticity, and organization, 
directly affect cell proliferation and invasion (Alexander et al., 2008; Lu et al., 2012). ECM 
stiffness, for example, is sensed by cells via integrins and focal adhesion components which 
link ECM to the cell cytoskeleton (Lu et al., 2012). ECM serves both as a barrier for tumor 
invasion, and provides anchorage for tumor invasion along its fibers (Alexander et al., 2008). 
Further, ECM binds many growth factors and cytokines, and limits their free diffusion and 
accessibility. Biochemical properties of the ECM also affect tumor cell proliferation and 
invasion. In tumors, ECM production, organization, and degradation are deregulated. Tumors 
are often stiffer than surrounding tissues (Lopez et al., 2011).  Mammographically dense 
breast tissue correlates with higher incidence of breast cancer (McCormack and dos Santos 
Silva, 2006). Consistently, Col1A1 overexpressing transgenic mice develop more breast 
adenocarcinomas than control mice, and the developed tumors are more invasive and 
metastatic (Provenzano et al., 2008). Overexpression of lysyl oxidase induces collagen 
crosslinking and tumor invasiveness (Levental et al., 2009). The production of many ECM 
components and their receptors, such as collagens type I, II, III, V, IX, CD44, is increased in 
cancer (Lu et al., 2012). In addition, the secretion of MMPs by tumor cells and stromal cells is 
induced (Kessenbrock et al., 2010).  
In addition to collagen, also the tenascin-C glycoprotein has also been implicated in 
carcinogenesis. Thus, it is upregulated in melanoma, and correlates with melanoma 
progression and metastasis (Tuominen and Kallioinen, 1994). Tenascin-C promotes stem cell-
like phenotype of melanoma cells and growth of melanoma spheres (Fukunaga-Kalabis et al., 
2010).  
Fibrinogen is often detected in tumors around blood vessels and at the tumor/host tissue 
interface and is associated with tumor progression (Costantini and Zacharski, 1992; Hotary et 
al., 2002). Xenograft tumors form significantly less distant metastases when grown in 
fibrinogen deficient mice compare to control mice, probably due to the lack of fibrinogen 
deposition around the circulating tumor cell emboli, which may promote tumor cell adhesion 
to the capillary walls of distant organs (Palumbo et al., 2002). 
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7.2 Non-malignant cells in tumor stroma 
 
Tumor cells affect non-malignant cells in tumor stroma, which differentiate from tumor-
suppressing to tumor-supporting cells. Cancer associated fibroblasts (CAFs) are irreversibly 
activated cells probably derived from normal fibroblasts, epithelial and endothelial cells, or 
cancer cells themselves (Petersen et al., 2003; Xing et al., 2010). They express α-smooth 
muscle actin (α-SMA), reminding the phenotype of myofibroblasts contributing to wound 
healing (Xing et al., 2010). CAFs secrete fibrin, MMPs, hyaluronan, and promote both tumor 
cell and stromal cell invasion through multiple signalling pathways (Pasonen-Seppänen et al., 
2012; Xing et al., 2010). For example, IL-1α and bFGF secreted by melanoma cells induce 
CAFs to secrete MMP-1, which in turn promotes ECM degradation and melanoma cell 
invasion (Löffek et al., 2005). Furthermore, the interaction of melanoma cells with CAFs 
mediated by ADAM9 facilitates melanoma cell invasion (Zigrino et al., 2011). 
Another group of non-malignant cells in tumor stroma are the bone marrow derived 
cells (BMDCs), including macrophages, neutrophils, mast cells, myeloid cell-derived 
suppressor cells (MDSCs), and mesenchymal stem cells (Joyce and Pollard, 2009). In the past 
the presence of immune cells was considered to reflect host immune reaction against 
developing tumor. However, tumor cells can escape immune surveillance, and in addition can 
render immune cells to become tumor promoting (Joyce and Pollard, 2009).  
Tumor associated macrophages (TAMs) have complex pro- and antitumorigenic effects. 
TAM density often correlates with poor prognosis in breast cancer and melanoma (Makitie et 
al., 2001; Zhang et al., 2012b). High macrophage count in melanoma is associated with 
ulceration, Breslow thickness, mitosis rate, lymphocyte infiltration, vascular density and 
lymphatic vessel invasion (Chen et al., 2011; Storr et al., 2012). Tumor cells secrete 
chemokines which attract TAMs, which in turn secrete immunosuppressive cytokines, 
interleukin-10, TGF-β, and VEGF-A, further affecting tumor cell proliferation and 
angiogenesis (Balkwill, 2004). Macrophage colony–stimulating factor (CSF-1) promotes 
macrophage infiltration and tumor invasion in breast cancer transgenic model (Lin et al., 
2001). However, some report the positive correlation between TAM infiltration and patient 
survival (Bingle et al., 2002). Further, VEGF-A produced by macrophages is known to 
contribute to abnormal tumor vasculature and to inhibit tumor growth (Stockmann et al., 
2008), suggesting that the net effect of TAM infiltration may differ depending on tumor type, 
experimental conditions and other factors in tumor microenvironment (Bingle et al., 2002).  
 
7.3 Tumor angiogenesis 
 
Angiogenesis is the formation of new blood vessels from pre-existing ones. In the adult 
organs, it occurs during wound healing and menstruation cycle. Excessive or deregulated 
angiogenesis contributes to various pathological conditions, such as arthritis, inflammation, 
diabetic retinopathy, and cancer. In diseased tissues, angiogenesis is initiated if the balance 
between pro- and antiangiogenic factors is tilted towards stimulators, a phenomenon called 
“angiogenic switch” (Carmeliet, 2005). Endothelial cells (ECs) of an adult organism are 
mostly quiescent, and their turnover time is hundreds of days (Kalluri, 2003). During 
embryogenesis, angioblasts assemble to create primitive vascular plexus. This process is 
called vasculogenesis. During angiogenesis, in turn, endothelial cells sprout from pre-existing 
vessels after receiving signals from growth factors. The sprouting begins when one cell 
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becomes a tip cell, while the cells next to it become stalk cells and start to proliferate 
(Gerhardt, 2008).  
Tumor angiogenesis is a prerequisite for tumor growth beyond the size of ~1 mm 
(Carmeliet and Jain, 2000). Melanoma cells secrete many proangiogenic molecules, such as 
VEGF, bFGF, IL-8, PDGF and PlGF (Streit and Detmar, 2003). The proteoglycans of 
endothelial basement membrane (BM) sequester VEGF and bFGF, which are released by 
MMP-9 and MMP-2 derived from stromal and immune cells during tumor angiogenesis 
(Bashkin et al., 1989; Gengrinovitch et al., 1999; Kalluri, 2003). MMP-9 cleaves collagen 
type IV, causing the disorganization of BM. As MMP-dependent degradation of BM 
proceeds, both pro-angiogenic (early stages) and anti-angiogenic (later stages) cryptic sites or 
peptides are exposed (Kalluri, 2003; Petitclerc et al., 2000; Xu et al., 2001). The imbalance of 
pro- and antiangiogenic signals in tumors leads to abnormal vasculature. Tumor vessels are 
often fragile, hyperpermeable, and have gaps in pericyte lining. This leads to tumor hypoxia 
despite of high vessel density, and release of proangiogenic factors, which results in even 
more abnormal vessels (Ziyad and Iruela-Arispe, 2011).  
Blocking tumor angiogenesis as a cancer treatment option was proposed already in 1971 
(Busam et al., 1995). However, the prognostic value of blood vessel density in melanoma 
remains controversial. Some studies report inverse correlation of vascular density with 
survival (Graham et al., 1994; Kashani-Sabet et al., 2002; Vlaykova et al., 1999), while others 
report no correlation (Busam et al., 1995; Carnochan et al., 1991), or even positive correlation 
(Ilmonen et al., 1999). Vascular density is positively correlated with melanoma stage (Storr et 
al., 2012). Furthermore, the expression of miRNAs which target ApoE, an angiogenesis 
inhibitor, is positively correlated with melanoma metastasis (Pencheva et al., 2012). In 
addition, decreased tumor angiogenesis in MMP-13 knockout mice is associated with reduced 
melanoma xenograft growth as well as reduced lung and liver metastasis (Zigrino et al., 
2009). Serum levels of proangiogenic factors, such as VEGF, bFGF and IL-8, correlate with 
decreased patient survival (Ugurel et al., 2001). Overexpression of VEGF in melanoma cells 
induces tumor growth, vascularization, and lung colonization in mice (Claffey et al., 1996), 
though the effects of VEGF vary depending on its isoform (Yu et al., 2002). The expression 
of VEGF165 isoform in melanoma xenografts induces higher level of vascularization than 
expression of VEGF121, but the tumor growth rate remains comparable (Yu et al., 2002). 
Further, melanomas usually express VEGF121, which leads to moderate vascularization, 
suggesting that moderate vascularization would be sufficient or even optimal for melanoma 
growth (Yu et al., 2002). In addition, melanoma cells extracted from hypoxic areas and 
injected back to mice grow faster than melanoma cells extracted from the vicinity of a blood 
vessel (Yu et al., 2001). Consistently, the induction of tumor hypoxia can even promote tumor 
invasiveness and metastasis (Harris, 2002), which may partly explain the lack of clear 
correlation between vessel density, tumor growth and prognosis. An interesting feature of 
some aggressive melanomas is vascular mimicry, a phenomenon where melanoma cells are 
organised in fluid-conducting tubes which are not lined with endothelial cells (Hendrix et al., 
2003; Ribatti et al., 2012). 
The importance of tumor angiogenesis has led to the development of antiangiogenic 
therapy for cancer treatment. Antibody against VEGF-A (bevacizumab) and kinase inhibitors 
which target VEGFR (sorafenib, sunitinib) have been approved for treatment of several 
human cancers in combination with chemotherapy (Bergers and Hanahan, 2008). These 
inhibitors often demonstrate initial clinical benefit in many cancer types, but tumors rapidly 
43 
adapt and develop mechanisms to overcome the effects of angiogenesis inhibitors (Bergers 
and Hanahan, 2008). These mechanisms may include the secretion of other proangiogenic 
factors, such as FGF, angiopoetins, and ephrins, the recruitment of immune cells which can 
stimulate angiogenesis, and the recruitment of bone marrow-derived cells (BMDCs) which 
can form new vessels. In addition, hypoxia may induce tumor cell invasion which facilitates 
the co-option of pre-existing vasculature, leading to distant organ colonizaion (Bergers and 
Hanahan, 2008; Casanovas et al., 2005). 
 
7.4 Tumor lymphangiogenesis 
 
Lymphangiogenesis has been much less explored than angiogenesis, since until recently 
no specific markers for lymphatic vessels have been known. During the last few years, 
however, this area of research has gained increasing attention, and especially evaluation of the 
functions of the lymphatic vessels in tumor progression has become possible. Markers 
currently used for detecting lymphatic vessels include LYVE-1 (Prevo et al., 2001), 
podoplanin (Kahn et al., 2002; Weninger et al., 1999), VEGFR-3 (Kaipainen et al., 1995), and 
PROX-1 (Wigle and Oliver, 1999). Lymphangiogenesis is generally induced by VEGF-C and 
VEGF-D, which bind to their receptor VEGFR-3 expressed by lymphatic endothelial cells 
(LECs) (Stacker et al., 2002).  VEGF-C can also bind to VEGFR-2 expressed by blood vessel 
endothelial cells (BECs) and LECs (Stacker et al., 2002). Some report that in tumors with 
high interstitial pressure no lymphangiogenesis or no functional intratumoral lymphatics may 
exist, and tumor cells are spreading via peritumoral lymphatics (Padera et al., 2002; van der 
Schaft et al., 2007). However, there is strong evidence for the existence and functionality of 
intratumoral lymphatics (Beasley et al., 2002; Skobe et al., 2001; Van der Auwera et al., 
2005). This discrepancy can be explained by different cancer types examined and models 
used (Alitalo and Detmar, 2012; Beasley et al., 2002; Van der Auwera et al., 2005). Even the 
tumor growth pattern can affect lymphangiogenesis. Thus, although lymphatic density is 
higher in infiltrating breast tumors growing around the host structures, lymphangiogenesis is 
stronger in breast tumors which grow in an expansive manner destroying pre-existing 
lymphatics (Van der Auwera et al., 2005). Nowadays it is widely accepted that at least in 
tumors which spread primarily through lymphatics, such as breast cancer, prostate cancer, and 
melanoma, the intratumoral lymphatics are functional (Alitalo and Detmar, 2012; Burton et 
al., 2008). Tumor cells induce lymphangiogenesis also inside sentinel lymph node metastasis, 
which further promote the formation of postsentinel metastasis (Kerjaschki et al., 2011). 
Interestingly, tumors induce lymphangiogenesis also in the sentinel lymph nodes even before 
metastatic cells arrive there (Hirakawa et al., 2005). 
Tumor lymphangiogenesis can be induced by VEGF-C secreted by both tumor cells and 
immunity cells, such as macrophages (Alitalo and Detmar, 2012; Moussai et al., 2011). The 
lymphatic density of the tumors correlates with lymph node metastases and decreased patient 
survival in breast cancer and melanoma (Alitalo and Detmar, 2012; Choi et al., 2005; Dadras 
et al., 2003; Dadras et al., 2005; Massi et al., 2006; Mohammed et al., 2009; Nakamura et al., 
2005; Ran et al., 2010). Inhibition of VEGFR-3 can restrict lymphangiogenesis and lymph 
node metastasis in mouse xenograft assays (Alitalo and Detmar, 2012; Burton et al., 2008; He 
et al., 2005). The increased ratio of peritumoral/intratumoral lymphatic vessels appears to 
predict lymph node metastasis better than the overall lymphatic vessel density (LVD, Dadras 
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et al., 2005; Shayan et al., 2012). Others have reported that intratumoral LVD is a more 
significant factor predicting sentinel lymph node metastasis than peritumoral LVD (Massi et 
al., 2006). Tumor lymphatics express specific markers, which can be used to home the 
cytotoxic peptides to the tumors (Laakkonen et al., 2008).  
 
7.5 Vascular and lymphatic intravasation of tumor cells 
 
Metastatic spread both to local sites (satellite metastasis/ in transit metastasis) or distant sites 
occurs via vascular or lymphatic system. The first step of this process is intravasation of 
tumor cells into intra- or peritumoral blood and lymphatic vessels. Some cancers, such as 
melanoma or breast cancer, metastasize in the early stages to the regional lymph nodes, while 
others, such as soft tissue sarcoma, engage almost solely in haematogenous spread (Leong et 
al., 2011).  
To date the mechanisms of intravasation have remained largely unknown. It is unclear if 
tumor cells actively invade into vessels, or whether they are passively pushed (Bockhorn et 
al., 2007). Intratumoral imaging techniques have revealed that breast cancer cells actively 
orient toward the blood vessels before entering the circulation (Wyckoff et al., 2000). Blood 
vessel invasion seems to require active permeabilization of blood vessels by tumor cells 
(Stoletov et al., 2007), while lymphatic vessels may permit passive tumor cell passage since 
they have discontinuous basement membrane and intraendothelial channels (Azzali, 2007). 
Further, VEGF-C and VEGF-D released by tumor cells induce peritumoral lymphatic vessel 
dilation and sprouting, which makes them even more permissive for passive tumor cell entry 
(He et al., 2005). 
The factors which affect the preference of tumor cells to intravasate into blood or 
lymphatic vessels are getting better understood. Several studies have indicated that circulating 
tumor cells are nonviable, but it remains to be seen whether they die in the circulation, or 
whether dead cells are passively shed into the circulation. Consistently, the number of 
circulating tumor cells does not directly correlate with the amount of metastatic colonies 
(Butler and Gullino, 1975; Fidler, 2003). In contrast, the presence of tumor cells in the 
regional lymph nodes predicts the risk of distant metastasis. Further, the ability of tumor cells 
to invade into lymphatic vessels, but not blood vessels, correlates with lung metastases in 
breast cancer xenografts (Giampieri et al., 2009). In addition, malignant cells often express 
endothelial adhesion receptors, which may facilitate their adhesion and extravasation. Some 
tumors also express the same chemokine receptors as immunity cells, which, when stimulated 
by chemokines released from lymphatic endothelial cells, can guide tumor cells to the 
draining lymph nodes (Muller et al., 2001; Wiley et al., 2001). Thus, some melanomas 
express CCR10, CCR7, and CXCR4. Inhibition of CCL12/CXCR4 signalling prevents breast 
cancer cell metastasis to the regional lymph nodes (Muller et al., 2001), and overexpression of 
CCR7 in B16 melanoma cells induces lymph node metastasis in mice (Wiley et al., 2001). 
Interestingly, lymphatic endothelial cells, but not blood endothelial cells, secrete CCL21, a 
ligand for CCR7 receptor often expressed by melanoma cells (Kriehuber et al., 2001). 
Lymphatic vessel invasion (LVI) has been detected in 16-63% of melanoma biopsies 
(Storr et al., 2012). It correlates strongly with sentinel lymph node status and decreased 
patient survival in breast cancer (Mohammed et al., 2009; Ran et al., 2010; Van der Auwera et 
al., 2005; van der Schaft et al., 2007) and melanoma (Egger et al., 2011; Niakosari et al., 
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2008; Petersson et al., 2009; Rose et al., 2011). In melanoma, LVI also correlates with the 
nodular subtype (Storr et al., 2012). Macrophages may promote LVI in melanoma (Storr et 
al., 2012). Shields et al. (2004) proposed the use of Shields index, which combines lymphatic 
density, Breslow thickness and LVI, and may predict overall survival even more accurately 
than Breslow thickness alone (Emmett et al., 2010; Shields et al., 2004).  
Blood vessel invasion (BVI) has been detected in 3-43% of melanoma biopsies, but it 
does not correlate with the disease stage or patient survival (Storr et al., 2012). In addition to 
melanoma, LVI is also more frequently observed than BVI in breast cancer (Ran et al., 2010). 
According to some reports, BVI also correlates with disease progression. HIF-1α, 
angiopoietin-like 4, and L1CAM in breast cancer cells promote transendothelial migration, 
BVI, and lung metastasis (Zhang et al., 2012a).  
 
7.6 MT-MMPs in angiogenesis and tumor progression 
 
MT-MMPs have been implicated in several key aspects of tumor progression, including 
tumorigenesis, local spreading, angiogenesis, tumor cell intravasation and extravasation. The 
upregulation of all six MT-MMP family members has been reported in various cancers (see 
5.2, Membrane-type matrix metalloproteinases).  
The fine balance between proteinases and their inhibitors tightly control the processes of 
angiogenesis, such as sprouting, vessel stabilization and regression. MT1-MMP is essential in 
several processes during angiogenesis. It induces both new vessel sprouting as well as 
pericyte recruitment (Lehti et al., 2005; Yana et al., 2007). MT1-MMP is expressed in 
developing large arteries during mouse embryogenesis (Apte et al., 1997). MT1-MMP 
deficient mice exhibit severe defects in angiogenesis (Zhou et al., 2000). For example, 
reduced vascularization of forming bones perturbs normal bone ossification in these mice. 
Further, in cornea angiogenesis assay, no formation of new blood vessels occurs in response 
to FGF treatment in MT1-MMP deficient mice (Zhou et al., 2000). VEGF and FGF -induced 
tube formation in 3D fibrin or collagen type I requires MT1-MMP but not MMP-2 activity 
(Chun et al., 2004; Lafleur et al., 2002). Melanoma cell -derived VEGF-A induces MT1-
MMP expression in cultured endothelial cells, leading to increased tube formation by ECs 
grown on 3D fibrin (Löffek et al., 2006). MT1-MMP in turn induces VEGF-A transcription 
via Src phosphorylation (Deryugina et al., 2002; Sounni et al., 2004). Further, MT1-MMP 
promotes tumor vascularization when overexpressed in MCF7 breast cancer cells, which do 
not normally express MT1-MMP (Sounni et al., 2002a). The expression of MT1-MMP is 
associated with BVI and lung metastasis, but not with LVI, in breast cancer (Perentes et al., 
2011). However, there are contrasting reports demonstrating that MT1-MMP downregulation 
does not affect blood vessel intravasation of fibrosarcoma cells (Deryugina et al., 2005). 
MT3-MMP is expressed together with MT1-MMP in endometrial microvascular endothelial 
cells, where it promotes tube formation in 3D fibrin (Plaisier et al., 2004).  
In addition to being involved in angiogenesis and tumor cell invasion, MT1-MMP can 
promote tumorigenesis by inducing malignant transformation of some cells. Thus, 
overexpression of MT1-MMP in non-malignant Madin-Darby canine kidney epithelial 
(MDCK) cells leads to the formation of invasive xenograft tumors in mice (Soulie et al., 
2005). MT1-MMP expression is also increased upon MDCK cell transformation by v-src or 
erbB2 (Kadono et al., 1998). Intracellular proteolytic activity of MT1-MMP against 
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pericentrin enhances chromosomal instability and may be one of the mechanisms how MT1-
MMP promotes tumor progression (Golubkov et al., 2005).  
The functions of MT-MMPs in tumor progression in vivo have been analyzed using 
transgenic mice, xenograft tumors, and in vivo metastasis assays (Deryugina and Quigley, 
2006). MT1-MMP overexpression in transgenic mice under the MMTV promoter results in 
mammary gland abnormalities, such as lymphocytic infiltration, periductal fibrosis, epithelial 
hyperplasia, and adenocarcinomas (Ha et al., 2001). Glioma xenografts overexpressing MT1-
MMP grow more rapidly, and exhibit higher angiogenesis and VEGF expression than control 
tumors (Deryugina et al., 2002). Similar results were obtained using breast adenocarcinoma 
and melanoma cells as a model (Sounni et al., 2002a; Sounni et al., 2002b). Moreover, MT1-
MMP promotes fibrotic reactions in pancreatic cancer transgenic mice via the induction of 
TGF-β activity (Krantz et al., 2011). 
Following the findings of MMP functions in tumor progression, MMP inhibitors have 
been developed for cancer treatment. They have reached phase III studies. However, while 
MMP inhibitors displayed marked inhibition of tumor progression in mice, the results of 
clinical studies have remained disappointing. This may be due to several factors. Broad-
spectrum MMP inhibitors lack specificity, which can be essential for successful treatment. 
Some MMPs, such as MMP-3 and MMP-8, have namely protecting properties in tumor 
progression (Agarwal et al., 2003; Balbin et al., 2003; McCawley et al., 2004). Inhibition of 
all MMPs also increases the frequency of various side effects, since most MMPs are required 
for normal tissue homeostasis. Further, drug concentration may have remained suboptimal 
due to adverse side effects. In addition, patients recruited for these studies have usually had 
late-stage metastatic disease, while the biggest benefit from MMP inhibitors is anticipated 
during initial stages of cancer, such as tumorigenesis, local invasion of primary tumor, as well 
as intravasation and extravasation processes of metastatic cells (Overall and Kleifeld, 2006; 
Sabeh et al., 2009). Therefore, better understanding of both protumorigenic and 
antitumorigenic functions of specific MMPs is needed for developing precisely targeted 
therapies.  
47 
AIMS OF THE STUDY 
 
The general purpose of this study was to elucidate the potential functions of MT-MMPs in 
melanoma invasion and pericellular proteolysis. The information of MT3-MMP and its 
biological functions and substrates in vivo is currently relatively scant. Since MT3-MMP was 
found to be associated with the aggressive nodular subtype of melanoma, we set our goal to 
elucidate the functions of MT3-MMP in melanoma cell invasion, and further on in melanoma 
growth in vivo. Furthermore, although many proteolytic enzymes can activate TGF-β when 
overexpressed or added ectopically, the roles of endogenous matrix-degrading proteases in the 
activation of TGF-β have remained poorly characterized.  
 
 
The specific aims included: 
 
1. To assess which endogenous enzymes release ECM-bound TGF-β in cultured 
endothelial cells 
 
2. To analyze the functions of MT3-MMP in melanoma invasion in different 3D matrices 
 
3. To evaluate the effect of MT3-MMP/MT1-MMP interactions on melanoma 
progression in in vivo xenografts 
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MATERIALS AND METHODS 
 
1. Cells lines 
 
The cell lines used have been listed below with their American Type Culture Collection 
(ATCC, Manassas, VA, USA) reference number or reference. Endothelial cell lines were 
grown in endothelial cell growth medium MV containing 2% of fetal calf serum (PromoCell), 
containing 50 μg/ml gentamicin. Other cell lines were grown in Eagle’s minimal essential 
medium (MEM) containing 10% heat-inactivated fetal calf serum (GIBCO), 100 IU/ml 
penicillin, and 50 μg/ml streptomycin. For stable overexpression, transfected Bowes cells 
were selected using G418 (400 μg/ml; Calbiochem). 
 
 
Cell line Description Reference number or 
reference 
HUVEC human umbilical vein endothelial cell line PromoCell, Heidelberg, 
Germany 
CCL-137 human embryonic lung fibroblasts ATCC; CCL-137 
Bowes human melanoma cell line, derived from 
RGP of melanoma 
ATCC; CRL-9607 
COS-1 African green monkey kidney epithelial 
cells, SV40 transformed 
ATCC; CRL-1650 




WM164 human melanoma cell line, derived from 
NM metastasis 
Wistar melanoma, Wistar 
Institute, USA 
WM165 human melanoma cell line, derived from 
SSM metastasis 
Wistar melanoma, Wistar 
Institute, USA 
WM293 human melanoma cell line, derived from 
SSM metastasis 
Wistar melanoma, Wistar 
Institute, USA 
WM739 human melanoma cell line, derived from 
VGP of SSM 
Wistar melanoma, Wistar 
Institute, USA 
WM852 human melanoma cell line, derived from 
NM skin metastasis 
Wistar melanoma, Wistar 
Institute, USA 
HDBEC primary juvenile foreskin lymphatic 
endothelial cell line 
PromoCell 
LEC primary juvenile foreskin lymphatic 
endothelial cell line 
PromoCell 
293FT human embryonal kidney cells, SV40 
transformed  







Antibodies used are listed below. Antibodies have been produced against human immunogens 
unless stated otherwise. 
 
Name Immunogen Description Use Source 
 LTBP-1 mouse 
(MAB388) 
IB (I) R&D Systems, Minneapolis, 
MN USA 
 β1-LAP goat (AF-
246-NA) 
IB (I) R&D Systems 
Ab39 LTBP-1 rabbit IB, IF (I) Dr. C.-H. Heldin, Ludwig 
Institute for Cancer Research 
Uppsala, Sweden 
 LTBP-2 rabbit IB, IF (I) (Hyytiäinen et al., 1998) 
 Fibronectin rabbit IF (I) Sigma, St. Louis, MO, USA 
 Collagen IV goat IF (I) Chemicon, Temecula, CA, 
USA 
 Laminin rabbit IF (I) Chemicon 
680 β1-LAP rabbit IB (I) (Taipale et al., 1994) 
 ERK1/2 rabbit IB (I) Promega, Madison, WI, USA 
 P-p44/42 rabbit IB (I) Cell Signalling, Beverly, MA, 
USA 
Ab-2 MT1-MMP, 
cytoplasmic tail  
rabbit IB, IP (II) (Lehti et al., 1998) 
RP1 MT1-MMP, hinge 
domain 
rabbit IF (II) Triple Point Biologics, Forest 
Grove, OR, USA 
 MT1-MMP, 
Ab6004 




mouse IB, IF, IHC 
(II, III) 
Millipore, Billerica, MA, 
USA 
 Hemagglutinin mouse IB (II) Covance, Princeton, NJ, USA 
 MT3-MMP rabbit, 
ab38968 
IB, IP (II) Abcam, Cambridge, UK 
Ab318 MT3-MMP, hinge 
domain 
rabbit IB, IP (II) Dr. R. Fridman, Wayne State 
University, Detrot, USA 
 mouse Lyve-1 rabbit IHC (III) (He et al., 2005) 
 collagen type I goat IF (III) Millipore 
 mouse CD31 rat IHC (III) BD Biosciences, Franklin 
Lakes, NJ, USA 
 mouse collagen 
type I 
rabbit IF (III) Millipore 
 mouse collagen 
type IV 
rabbit IF (III) Millipore 
 fibrinogen rabbit IHC (III) Daco, Glostrup, Denmark 
 S100 rabbit IHC (III) Daco 
 human CD31 mouse IF (III) Daco 
 human Prox-1 goat IF (III) R&D Systems 
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3. Other reagents 
 
Reagent Source Used in 
PMA Sigma I 
TAPI-1 (MMP inhibitor) Millipore I 
GM6001 (MMP inhibitor) Millipore I, II, III 
AEBSF (serine protease inhibitor) Millipore I 
LY294002 (PI-3K inhibitor) Millipore I 
Bisindoylmaleimide-1 (PKC inhibitor) Millipore I 
PD98059 (MEK inhibitor) Millipore I 
DRB (casein kinase-II inhibitor) Enzo Life Sciences, Farmingdale, 
NY, USA 
I 
Aprotinin (serine protease inhibitor) Sigma I, II, III 
UO126 (MEK inhibitor) Promega I 
Phalloidin-TRITC Sigma II, III 
Collagen type I rat tail, acid-extracted Sigma II, III 
Bafilomycin A1 (lysosomal inhibitor) Millipore II 
Human recombinant HGF R&D Systems II 
Fibrinogen Millipore II, III 
Thrombin Sigma II, III 
 
4. RNA interference  
 
293FT producer cells were cotransfected with the packaging plasmid (pCMVdr8.74), 
envelope plasmid (pMD2-VSVG) and shRNA-plasmid (hairpin-pLKO.1 vector) or control 
plasmid (scrambled) using Lipofectamine 2000. The viral supernatants were harvested for 48 
h, filter sterilized and transferred to target cells. After 16 h infection the supernatants were 
replaced with complete media for the subsequent assays. The knockdown efficiency was 
assessed by quantitative PCR (qPCR) after 48 h. For stable shRNA expression cells were 
selected using puromycin (5 μg/ml). Small interfering RNAs (siRNA) were transfected using 
Lipofectamine™ 2000 (Life Technologies). 
 
 
Name Source Used in 
Scrambled shRNA in pLKO.1 vector Open Biosystems I, II, III 
MT1-MMP shRNA, Cstr-1 Open Biosystems, TRCN0000050854 I 
MT1-MMP shRNA, Cstr-2 Open Biosystems, TRCN0000050855 I 
MT1-MMP shRNA, Cstr-3 Open Biosystems, TRCN0000050856 I 
MT1-MMP shRNA, Cstr-4 Open Biosystems, TRCN0000050857 I 
Negative control siRNA Qiagen, 1027280 II, III 
MT1-MMP siRNA Qiagen, SI03648841 II, III 
MT1-MMP siRNA Qiagen, MMP14sIR1Q II 
MT3-MMP siRNA Qiagen, SI00083006 II, III 
MT3-MMP siRNA Qiagen, MMP16sIR1Q-1 II 
MT3-MMP shRNA, shMT3-1 Open Biosystems, TRCN0000052249 II 
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MT3-MMP shRNA, shMT3-2 Open Biosystems, TRCN0000052250 II, III 
MT3-MMP shRNA, shMT3-3 Open Biosystems, TRCN0000052251 II 
 
5. Expression constructs (II) 
 
The following expression vectors were transfected using FuGENE (Roche, Penzberg, 
Germany) or TransIT-2020 (Mirus, Madison, WI, USA): MT3-MMP, MT1-MMP, MT1-
MMP with inactivating E240A point mutation (MT1E/A), HA-tagged MT1-MMP (Hotary et 
al., 2002; Lehti et al., 2000; Li et al., 2008), inactive MT3-MMP E247A construct (MT3E/A) 
kindly provided by Dr. D. Pei (Kang et al., 2000). Rescue constructs for MT3-MMP with 
double silent mutations in shMT3-2 binding sequence rescMT3-1 (T822C-T825C) and 
rescMT3-2 (T831C-A836C) were generated using QuikChange® Site-Directed Mutagenesis 
Kit (Agilent Technologies, Santa Clara, CA, USA).  
 
6. Immunofluorescence analysis (I, II, III) 
 
The cells on glass coverslips were fixed with 4% PFA for 5 min at +4°C followed by blocking 
and permeabilization in 5% BSA/0.1% Triton X-100/PBS for 30 min RT, and staining with 
the indicated primary antibodies (1 h) and Alexa Fluor-labeled secondary antibodies (30 min, 
Life Technologies). The coverslips were finally mounted on glass slides using Vectashield 
anti-fading reagent (Vector Laboratories) and examined using the Axioplan microscope 
(Zeiss). For immunofluorescence staining of the mouse tumor frozen sections, sections were 
post fixed with cold methanol-acetone, blocked with 15% fetal calf serum/0.3% Triton X-
100/Dulbecco for 1 h, followed by staining with the indicated primary antibodies (1 h) and 
Alexa Fluor-labeled secondary antibodies (30 min). The sections were then mounted with 
Vectashield anti-fading reagent. 
 
7. Isolation and plasmin digestion of ECM-associated proteins (I) 
 
The cell cultures were washed once with PBS and lysed by 0.5% sodium deoxycholate 
(NaDOC) in 10 mM Tris–HCl buffer, pH 8.0, containing 150 mM NaCl and 1% NP-40, and 
clarified by centrifugation at 8000 ×g for 10 min (Taipale et al., 1994). The NaDOC insoluble 
material was then washed once with ice-cold PBS and digested with 0.3 U/ml of plasmin 
(Sigma) in PBS containing 1mM MgCl2, 1 mM CaCl2 and 0.1% n-octyl-β-D-glucopyranoside 
(Sigma) at 37°C for 2 h. Protease inhibitors (Complete® protease inhibitor cocktail, Roche) 
were then added, and the supernatants were clarified by centrifugation. Subsequently, the 





8. SDS-PAGE and immunoblotting (I, II) 
 
Cells were lysed with RIPA buffer (150 mM Tris-HCl pH 7.5, 150 mM NaCl, 1% Triton X-
100, 0.5% sodium deoxycholate, 0.1% SDS) containing Complete® protease inhibitor 
cocktail (Roche). Equivalent quantities of proteins were size-fractionated by gradient (4–20%) 
SDS-PAGE followed by transfer to polyvinylidene difluoride membranes. The non-specific 
protein binding sites were saturated with 5% non-fat milk in TTBS-buffer (TBS containing 
0.05% Tween-20) for 30 min. The membranes were washed with TTBS and incubated with 
primary antibodies overnight, and with HRP-conjugated secondary antibodies (Dako) for 30 
min, and the bound antibodies were detected using enhanced chemiluminescence (Promega).  
 
9. Gelatin zymography (I, II) 
 
Polypeptides of the conditioned media were separated under nonreducing conditions using 
10% SDS-polyacrylamide gels containing 1 mg/ml of gelatin. After that the gels were washed 
twice with 50 mM Tris-HCl buffer, pH 7.6, containing 5 mM CaCl2, 1 μM ZnCl2 and 2,5% 
Triton X-100 for 15 min to remove SDS, followed by a brief rinsing in washing buffer 
without Triton X-100. Next, the gels were incubated at +37 °C overnight in the developing 
buffer, 50 mM Tris-HCl, pH 7.6, containing 5 mM CaCl2, 1 μM ZnCl2, 1% Triton X-100 and 
0.02% NaNO3. The gels were then stained with Coomassie Blue for 2 h and destained with a 
solution containing 10% methanol and 10% acetic acid. 
 
10. Isolation of RNA from cultured cells and human biopsies, reverse 
transcription and qPCR (I, II, III) 
 
Total cellular mRNA was isolated using RNeasy Mini kit (Qiagen) followed by reverse 
transcription with Random hexamer primers (Life Technologies) and Superscript III reverse 
transcriptase (Life Technologies). Total mRNAs from representative microdissected samples 
of archival paraffin-embedded biopsies of benign intradermal or compound melanocytic nevi, 
melanomas , and of adjacent normal skin were extracted using High Pure RNA Paraffin Kit 
(Roche). The biopsies had been removed for diagnostic purposes and the histological 
diagnosis had been confirmed by the University Hospital dermatopathologist. The cDNAs 
were amplified on GeneAmp 7500 Sequence Detector thermal cycler (Applied Biosystems) 
using TaqMan Universal PCR Master Mix and validated primers (MT1-MMP; Hs 
01037006_gH, MT2-MMP; Hs 00233997_m1, MT3-MMP; Hs 00234676_m1K; human 
col1A1, Hs00164004_m1; mouse col1A1, Mm00801666_g1; mouse col3A1, 
Mm01254476_m1; Applied Biosystems). The expression levels were normalized with TATA-
binding protein (TBP, Applied Biosystems) or GAPDH. TissueScan Melanoma Tissue qPCR 
Arrays I and II (OriGene Technologies) containing cDNAs from human tissue biopsies of 




11. Cell invasion and growth in three-dimensional collagen and fibrin (II, 
III) 
 
Cell invasion was assessed essentially as described (Hotary et al., 2000; Illman et al., 2006). 
Briefly, rat tail type I collagen (4.8 mg/ml) was mixed with equal amount of 2xMEM, and pH 
was adjusted to ~7.4 by NaOH. Collagen was cast in the upper chambers of Falcon cell 
culture inserts in 24 well plates and incubated at 37˚C for 1 h to allow gelling. Cross-linked 
fibrin gels were cast in the inserts by combining 75 μl plasminogen-free human fibrinogen (6 
mg/ml) in Hank’s Balanced Salt Solution (HBSS), and 75 μl HBSS (pH 7.4) containing 4 
U/ml human thrombin and 400 μg/ml aprotinin. The cells were seeded atop the matrix in the 
upper chamber in medium containing 1% FCS. HGF (25 ng/ml) and medium containing 10% 
FCS served as chemoattractants in the lower chambers, with medium changed every third 
day. After a 3-5 d culture period, the cells were fixed with 4% PFA, and paraffin sections 
were stained with hematoxylin and eosin (HE-staining). Sections were photographed, and the 
invaded cells were counted from 8 random sections of each sample. Each assay was 
performed in triplicate. For 3D growth/invasion assays, collagen (2.4 mg/ml) and fibrin were 
prepared as above. The cells (5000) were suspended in 40 μl hydrogel, the suspension 
transferred to a 24-well plate, and incubated at 37˚C for 1 h to allow complete gelling. After 5 
d incubation in complete growth medium, cultures were fixed and photographed using 
Axiovert 200 microscope (Carl Zeiss). Alternatively, collagen or fibrin gels were stained with 
phalloidin-TRITC to visualize filamentous actin, and photographed using Axioplan upright 
epifluorescence microscope (Carl Zeiss). The percentages of invasive colonies were 
calculated from 20 random phase-contrast or epifluorescence images of 6 separate gels. 
 
12. Northern hybridization (II) 
 
Total cellular RNA (10 μg) was fractioned by formaldehyde-agarose gel electrophoresis and 
transferred to a Zeta probe membrane (Bio-Rad) in 20 x SSC (1 x SSC: 150 mM NaCl, 15 
mM sodium citrate, pH 7.0) and fixed by UV crosslinking. cDNA probes corresponding to 
full-length MT1-MMP and MT3-MMP cDNA were labelled with [32P] dCTP by the random 
priming method (Amersham Pharmacia Biotech). The membranes were hybridized in 
ExpressHyb hybridization solution (Clonetech) at 58˚C for 16-24 h. Washing was carried out 
in 0.2 x SSC containing 0.1 % SDS at 63˚C. Glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) was used as an internal standard. 
 
13. Immunoprecipitation (II) 
 
Endogenous or recombinant MT1-MMP and MT3-MMP were immunoprecipitated from cell 
lysates by incubation with specific rabbit polyclonal and G protein Sepharose (GE 
Healthcare) at 4°C for 2 h. The Sepharose particles were then pelleted by centrifugation and 
washed extensively with PBS. The proteins were eluted with the sample buffer and separated 
for immunodetection by SDS-PAGE. 
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14. Cell surface labeling (II) 
 
Cell surface biotinylation was performed as described (Lehti et al., 1998). Briefly, cells were 
rinsed twice with PBS and incubated with 0.5 mg/ml biotin (Pierce) in PBS on ice for 1 h. 
The reaction was terminated by washing 3 times for 10 min each with 150 mM glycine/TBS. 
The cells were then lysed and subjected to immunoprecipitation with rabbit polyclonal MT1-
MMP or MT3-MMP antibodies. The immunoprecipitated material was resolved by SDS-
PAGE, and detected with horseradish-peroxidase-conjugated streptavidin (Daco).  
 
15. In vivo xenografts in mice (III) 
 
Experiments were approved by the State Provincial Office of Southern Finland. WM852 cells 
were lentivirally transduced with scrambled shRNA and shRNA targeting MT3-MMP 
(shMT3-2), and stable pools were selected by puromycin (Sigma). Cells were also retrovirally 
transduced with a Renilla luciferase – green fluorescent protein fusion reporter protein. Cell 
pools (1.3 x 10
6
 or 2.0 x 10
6
) were implanted into the abdominal subcutis of ICR-severe 
combined immunodeficient (SCID) female mice. Tumor volumes were measured with a 
caliper and calculated according to the formula V = width × height × depth / 2, derived from 
the formula for the volume of an ellipsoid (Laakkonen et al., 2007). After ~8 weeks, the 
tumors, the lymph nodes and organs were collected, fixed with 4% PFA, and embedded in 
paraffin or processed for frozen sections.  
 
16. Immunohistochemistry (III) 
 
Mouse xenograft tumors and lymph nodes were fixed with 4% paraformaldehyde, dehydrated, 
and embedded in paraffin. Alternatively, PFA-fixed tumors were incubated in 25% 
sucrose/PBS for 4 h, washed with PBS, and embedded in OCT Compound (Tissue-Tek) for 
frozen sections. For immunohistochemistry, tissue sections were de-paraffinized in 
TissueClear (Tissue-Tek) and re-hydrated in graded ethanol series. After antigen retrieval by 
boiling in sodium citrate buffer (10 mM sodium citrate, 0.05% Tween-20, pH 6), the sections 
were incubated for 10 min in 0.6% (v/v) hydrogen peroxide. The tissue sections were 
subsequently rinsed and incubated with 2.5% Normal Horse Serum (blocking buffer, Vector 
Laboratories) for 30 min. Primary antibodies were incubated o/n in blocking buffer, followed 
by incubation with peroxidase conjugated anti-mouse Ig/anti-rabbit Ig for 30 min. Detection 
was performed using Vectastain DAB kit according to manufacturer’s instructions. 
Alternatively, TSA™ Biotin System Kit (PerkinElmer) was used. After washes slides were 
dehydrated and mounted using Cytoseal mounting medium (Thermo Scientific). Images were 
taken using Leica DM LB microscope (Leica). 
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17. Melanoma cell co-culture with BEC and LEC spheroids in 3D fibrin 
(III) 
 
HDBEC and LEC cells (PromoCell) were cultured in Endothelial Cell Growth Medium MV 
(PromoCell). Endothelial cell spheroids were formed in non-adherent conditions by culturing 
4000 cells/well in agarose coated 96-well round bottom plate o/n. Ten to twelve endothelial 
cell spheroids were then mixed with 5000 melanoma cells pretreated with green fluorescent 
Vybrant
®
 CFDA SE Cell Tracer (Life Technologies), and 50 μl 3mg/ml fibrin was formed as 
described above. After gelling at 37˚C for 30 min, Endothelial Growth Medium MV 
supplemented with 100 ng/ml aprotinin (Sigma-Aldrich) was added to the cultures. After 3 d, 
the cells were fixed with 4% PFA and subjected to immunofluorescence staining with anti-
CD31 (Dako) antibodies. The spheroids were then mounted with Vectashield (Vector 
Laboratories) and imaged using Leica TSC SP5 confocal microscope (Leica).  
 
18. Cell adhesion assay (III) 
 
Melanoma cells treated with green fluorescent Vybrant® CFDA SE Cell Tracer were seeded 
on lymphatic (LEC) or blood vessel (HUVEC) cell monolayers in 96-well plates. After 1 h 
unadhered cells were removed by washing 3 times with PBS. The adherent cells were fixed 
with 4% PFA. Nuclei were then stained with Hoechst (Sigma). The number of adhered 
melanoma cells/well was analyzed using Cellomics View software (Thermo Scientific). 
 
19. Transendothelial migration assay (III) 
 
Melanoma cells pretreated with green fluorescent Vybrant® CFDA SE Cell Tracer were 
seeded upon LEC or HDBEC monolayers on a gelatin coated semipermeable membrane of 
Falcon cell culture inserts in endothelial growth medium containing 1% serum. Medium 
containing 10% fetal calf serum was used in the lower chamber as an attractant. After 12 h the 
cells were fixed, and the cells from upper chamber were removed by wiping. The membranes 
were mounted on the objective glasses and photographed with upright fluorescent microscope 
Axioplan (Zeiss). The areas of transmigrated cells/microscopic field were quantified using 
ImageJ software. 
 
20. Statistical analysis (II, III) 
 
All numerical values represent mean ± SD. Statistical significance was determined using the 






1. Large latent TGF-β complex (LLC) is released from the ECM upon 
endothelial cell activation (I) 
 
Most non-malignant cells secrete TGF-β as a large latent TGF-β complex (LLC). LTBP-1 
regulates the secretion, availability and activation of TGF-β by facilitating its secretion and by 
targeting LLC to the ECM. The release of LLC from ECM is considered to be among the first 
steps in TGF-β activation. Culturing HUVEC endothelial cells for 4 d resulted in massive 
deposition of LTBP-1 into the subendothelial matrix. Activation of endothelial cells with 
PMA (phorbol 12-myristate 13-acetate) caused morphological transformation from 
cobblestone-like to fibroblastoid spindle cell appearance. Similar morphological changes can 
be induced by inflammatory cytokines, such as IL-1β, INF-γ, and TNF-α (Bujan et al., 1999; 
Koziol et al., 2012; Montesano et al., 1985). During this process, LTBP-1 was almost 
completely depleted from the ECM in conjunction with the release of truncated LTBP-1 and 
LLC, as well as traces of LTBP-1 -free small latent TGF-β complex (SLC), and translocated 
into the conditioned medium. The depletion of LTBP-1 and LLC from the ECM was almost 
complete after 48 h. As analyzed by immunofluorescence, collagen type IV was also depleted 
from the ECM, and the amount of laminin was reduced. In addition, fibronectin and LTBP-2 
staining patterns became fragmented. PMA is a direct protein kinase C agonist, which induces 
also Erk1/2 phosphorylation and PI-3 kinase pathway (Taylor et al., 2006). The 
morphological change and processing of LTBP-1 induced by PMA were abrogated by PKC 
and MEK inhibitors, but only slightly by PI-3 and CK-II inhibitors.  
 
2. Silencing of MT1-MMP abrogates the release of TGF-β from the 
subendothelial matrix (I) 
 
Since proteases such as MMP-2, MMP-9, and serine proteases have been implicated in TGF-β 
release from the ECM or TGF-β activation (Dallas et al., 2002; Taipale et al., 1992; Taipale et 
al., 1995; Yu and Stamenkovic, 2000), we defined by protease inhibitors which endogenous 
proteases participate in TGF-β release from endothelial cell ECM. LTBP-1 and LLC release 
from the ECM was inhibited by synthetic wide spectrum MMP and ADAM inhibitors TAPI-1 
and GM6001, but not by serine protease inhibitors. Further, morphological activation of 
endothelial cells by PMA was associated with induction of MMP-2 activation, reflecting 
increased MT-MMP activity. MT1-MMP was the only notably expressed MT-MMP in 
HUVECs, and its expression was further enhanced by PMA. Both ADAM10 and -17 were 
also expressed in these cells, but their expression was not affected by PMA. To assess which 
MMPs or ADAMs contributed to LLC release from the ECM, we assessed the effect of tissue 
inhibitors of metalloproteinases, TIMP-1, -2 and -3, which have different specifities towards 
MMPs. TIMP-1 inhibits mainly secreted MMPs and ADAM10, while TIMP-2 inhibits 
secreted and membrane-type MMPs, and TIMP-3 inhibits all MMPs and ADAM10 and -17, 
among others (Baker et al., 2002). Since TIMP-2 and TIMP-3, but not TIMP-1, abrogated 
57 
LTBP-1 and LLC release from the ECM, we concluded that MT-MMPs mediated LTBP-1 
cleavage in activated endothelial cells. Indeed, specific silencing of MT1-MMP by lentiviral 
short hairpin RNA reversed LTBP-1 depletion from the ECM, indicating that MT1-MMP 
mediated LLC release from the subendothelial matrix.  
 
3. MT3-MMP is expressed in lymph node metastases of melanoma and in 
metastatic melanoma cell lines (II) 
 
In addition to promoting angiogenesis MT1-MMP has important functions in cancer cell 
invasion and metastasis. In melanomas MT1-MMP is often overexpressed in the invading 
edges of primary tumors, and its expression is associated with melanoma metastatic 
progression (Hofmann et al., 2000; Riker et al., 2008). Its close homologue, MT3-MMP, is 
specifically expressed in the most aggressive melanoma subtype, nodular melanoma (Jaeger 
et al., 2007; Ohnishi et al., 2001), but its functions in cancer progression are largely unknown. 
To begin to characterize MT3-MMP functions in melanoma progression, we assessed MT1-
MMP and MT3-MMP mRNA expression in human biopsy samples of normal skin, benign 
nevi, and metastases to lymph nodes and different organs. MT1-MMP and MT3-MMP were 
not upregulated in benign nevi compared to normal skin. Remarkably, MT3-MMP was 
upregulated >8-fold in biopsies of lymph node metastases compared to normal skin. In 
contrast, MT1-MMP expression was high in normal skin and benign nevi, but was not 
significantly increased in biopsies of metastases. 
In parallel, we assessed the expression of MT1-MMP and MT3-MMP in cultured 
melanoma cell lines derived from primary tumors and metastases. MT1-MMP was expressed 
in four metastatic cell lines (WM852, WM164, WM165 and WM239) and in three cell lines 
derived from primary tumors (Bowes, G361, WM793). MT3-MMP was expressed in three 
metastatic cell lines (WM852, WM165 and WM239) and WM793 cell line derived from 
vertical growth phase primary melanoma, suggesting that MT3-MMP might be associated 
with melanoma progression. 
 
4. MT3-MMP promotes the adhesive phenotype of melanoma cells in 
conjunction with increased fibrin invasion and restricted collagen invasion 
(II, III) 
 
MT1-MMP drives tumor cell invasion through collagen type I and the basement membranes. 
It localizes often to invasive structures of the cells, where it cleaves native collagen type I and 
other ECM proteins to permit tumor cell movement (Ota et al., 2009; Sabeh et al., 2004). 
Although MT3-MMP is a close homologue of MT1-MMP, it cannot cleave collagen type I, 
but it cleaves collagen type III, fibrin, and laminin (Li et al., 2008; Sabeh et al., 2004; 
Shimada et al., 1999). To investigate the growth and invasion of melanoma cells in 3D 
conditions, we implanted them as single cells in cross-linked acid-extracted collagen type I. 
Remarkably, we found that MT3-MMP expression was associated with expansive growth of 
melanoma colonies or growth as rounded single cells, while cells with undetectable MT3-
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MMP expression grew in collagen as invasive sprouting colonies or elongated single cells. To 
further analyze the invasive phenotypes of melanoma cells, we plated WM852 and Bowes 
cells atop 3D collagen type I and fibrin, which is a component of provisional matrix found in 
melanoma tumor/host interface. WM852 cells, derived from nodular melanoma metastases 
and expressing MT3-MMP, displayed marked fibrin-invasive activity and limited collagen 
invasion. Bowes cells, derived from radial growth phase melanoma and not expressing MT3-
MMP, invaded efficiently into both matrices. Consistently with previous reports on the 
functions of MT-MMPs in cell invasion (Hotary et al., 2000; Hotary et al., 2002; Sabeh et al., 
2004), both the collagen and fibrin invasion were abrogated by the MMP inhibitor. MT1-
MMP silencing inhibited collagen and fibrin invasion of WM852 cells. Remarkably, MT3-
MMP silencing promoted collagen invasion but inhibited fibrin invasion in these cells. 
Furthermore, stable overexpression of MT3-MMP in Bowes cells resulted in marked increase 
in fibrin invasion and significant attenuation of collagen invasion. 
To assess the interrelated functions of MT-MMPs in cell invasion, we expressed MT1-
MMP and MT3-MMP alone or in combination in COS cells, which lack endogenous MT-
MMPs. COS cells expressing MT1-MMP invaded efficiently both 3D collagen and fibrin, 
whereas cells expressing MT3-MMP invaded only into fibrin. Interestingly, co-expression of 
MT1-MMP and MT3-MMP further induced fibrin invasion of COS cells, but abrogated 
collagen invasion, suggesting that MT3-MMP reduced collagenolytic activity of MT1-MMP. 
In 2D cell culture, WM852 cells overlaid with 3D collagen grew as cohesive colonies. 
MT3-MMP silencing resulted in morphological shift from cohesive growth pattern to single 
cell growth. Furthermore, MT3-MMP silencing induced reduction of ZO-1 in cell-cell 
contacts. To further elucidate the functions of MT3-MMP in melanoma cell invasion, we 
stably silenced MT3-MMP in WM852 and WM165 melanoma cells using lentiviral shRNA. 
Stable MT3-MMP silencing resulted in profound induction of sprouting growth pattern and 
invasion in 3D collagen. In contrast, MT3-MMP silencing markedly reduced the invasive 
growth of melanoma cells in 3D fibrin, indicating that endogenous MT3-MMP supports 
cohesive growth of 2D cultures and promotes fibrin invasion of melanoma cells, whereas in 
collagen it shifts their growth from invasive to expanding type.  
 
5. MT3-MMP restricts the collagenolytic activity of MT1-MMP by cleaving 
it and reducing its cell surface localization (II, III) 
 
Both MT1-MMP and MT3-MMP undergo autocatalytic inactivation, which generates 44 kDa 
and 37 kDa cell-bound fragments, respectively (Lehti et al., 1998). When MT3-MMP was 
stably expressed in Bowes cell, it was detected in cell lysates mainly as a processed 37 kDa 
form, and as a ~65 kDa form on the cell surface. Full-length ~65 kDa protein was markedly 
increased in cell lysates after inhibition of both MMP and lysosomal activities, indicating that 
autocatalytic processing and subsequent internalization and lysosomal degradation resulted in 
rapid MT3-MMP turnover. MT3-MMP reduced both the endogenous and ectopically 
expressed full-length MT1-MMP in Bowes cells lysates and induced the processing of 
ectopically expressed MT1-MMP to 37-44 kDa fragments in Bowes and COS cells. Since 
MT3-MMP induced the cleavage of catalytically inactive MT1-MMP E/A mutant, we 
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concluded that MT3-MMP cleaved MT1-MMP directly rather than induced its autocatalytic 
cleavage.  
Oligomerization of MT1-MMP promotes the autocatalytic cleavage of MT1-MMP and 
proMMP2 activation (Lehti et al., 2002). We found that MT1-MMP was co-
immunoprecipitated with MT3-MMP in Bowes and COS-1 cells, suggesting that they existed 
in the same complexes on the cell surface. Further, when MT1-MMP was expressed in COS 
cells, which lack endogenous MT-MMPs, it was detected mainly on the cell surface by 
surface biotinylation and immunofluorescence. In contrast, co-expression of MT1-MMP with 
catalytically active MT3-MMP resulted in the shift of MT1-MMP localization from cell 
surface to mainly intracellular. Consistently, stable silencing of MT3-MMP by lentiviral 
shRNA in WM852 cells resulted in induction of MT1-MMP on the cell surface both in cell 
culture in vitro and in melanoma xenografts in vivo. 
 
6. Silencing of MT3-MMP increases the growth rate of melanoma 
xenografts and induces a switch from lymphatic to blood vessel invasion 
(III) 
 
To investigate MT3-MMP functions in melanoma progression in vivo, tumor growth and 
invasion were analyzed after subcutaneous injection of WM852 cells expressing control 
shRNA (Ctrl) and shRNA targeting MT3-MMP (shMT3) into SCID mice. The control tumors 
grew slowly, reaching the average weight of 0.24 ± 0.1 g in ~8 weeks. MT3-MMP silencing 
induced the growth rate of tumors, which reached the average weight of 0.55 ± 0.2 g during 
the same period of time. Similar results were obtained from two independent experiments. 
To analyze tumor blood and lymphatic vessel density, tumor sections were stained by 
CD31 and LYVE-1, a panendothelial marker and a marker for lymphatic vessels, 
respectively. Intratumoral blood and lymphatic density in shMT3 tumors was slightly 
reduced, while peritumoral lymphatic densities remained comparable. Notably, we observed 
marked lymphatic vessel invasion (LVI) by tumor cells in the control group, which was 
abrogated by MT3-MMP silencing. LVI was more prominent in peritumoral than intratumoral 
vessels. By contrast, negligible blood vessel invasion (BVI) of control tumors was increased 
by ~10-fold after MT3-MMP silencing. 
 
7. Silencing of MT3-MMP affects the ECM composition of melanoma 
xenografts (III) 
 
Since MT-MMPs are strong modulators of ECM, we analyzed ECM composition of control 
and shMT3 tumors. Collagen type IV thickness at vascular basement membrane was 
comparable in both groups. In contrast, prominent collagen type I fibers in control tumors 
were markedly decreased after MT3-MMP silencing as detected by both immunofluorescence 
and immunohistochemistry. The mRNA expression of human collagen type I and mouse 
collagen type I and III in mouse xenografts remained comparable, suggesting that collagen 
degradation was enhanced. By contrast, control tumors displayed only minor amounts of 
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extracellular fibrin, and MT3-MMP silencing resulted in prominent fibrin extracellular 
network detected by immunohistochemistry. Consistently with the observed increase of 
collagen degradation in shMT3 tumors, MT1-MMP localization shifted from mainly 
intracellular in control tumors to cell surface after MT3-MMP silencing. 
 
8. Three-dimensional matrix facilitates melanoma cell transmigration 
across LECs (III) 
 
To define the contribution of ECM composition and melanoma/endothelial cell interactions in 
intravasation, we cultured melanoma cells atop blood endothelial cell (BEC) and lymphatic 
endothelial cell (LEC) monolayers. WM852 melanoma cells adhered efficiently to human 
BECs but poorly to LECs. Silencing of MT3-MMP further increased adhesion to BECs, 
whereas adhesion to LECs was less affected. Furthermore, only few melanoma cells 
transmigrated across the LEC monolayer within 12 h, whereas transmigration across the BEC 
monolayer was efficient. The transmigration of the cultured cells across BECs was further 
enhanced after MT3-MMP silencing. To better mimic tumor cell-endothelial cell interactions 
and intravasation in the ECM microenvironment, we cultured melanoma cells together with 
BEC and LEC spheroids in 3D fibrin gels. Opposite to the weak transmigration across LEC 
monolayer, control WM852 melanoma cells efficiently invaded into the bodies of LEC 
spheroids grown in fibrin, suggesting that 3D matrix may facilitate transmigration. The cell 
invasion into both LEC and BEC spheroids was decreased after MT3-MMP silencing, which 
is in line with limited ability of these cells to invade in the fibrin matrix. Therefore, MT3-
MMP expression supports intravasation of WM852 cells into 3D LEC spheroids.  
 
9. Low MT1-MMP and/or high MT3-MMP expression correlates with 
cohesive growth phenotype of human melanoma tumors (III) 
 
To investigate the functions of MT3-MMP in human melanoma tumors, we assessed MT1-
MMP and MT3-MMP expression and collagen content in eight melanoma biopsies. For 
mRNA expression benign nevus biopsies were used as a control. MT1-MMP expression was 
markedly elevated in three melanoma biopsies, and MT3-MMP expression was increased in 
two melanoma biopsies compared to benign nevi. In the eight Herovici-stained melanoma 
biopsy specimens, five tumors exhibited cohesive morphology with expansive melanoma cell 
nests surrounded by collagen fibers. All of these tumors had either low MT1-MMP or high 
MT3-MMP expression. Three melanomas exhibited infiltrating growth pattern. Two of these 
melanomas had high MT1-MMP and low MT3-MMP expression, and in one melanoma both 
MT1-MMP and MT3-MMP were low. In addition, we stained two whole tumor specimens 
with highest MT1-MMP expression for podoplanin to detect lymphatic vessels. M4 tumor 
expressed high MT3-MMP mRNA, and M7 tumor expressed low MT3-MMP, resembling the 
expression pattern of control and shMT3 WM852 cells. Notably, M4 tumor exhibited 
prominent lymphatic invasion, whereas no lymphatic invasion was observed in M7 tumor. 
Similar to cohesive growth in 2D culture and low collagenolytic ability of WM852 cells, 
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melanoma cells of M4 tumor grew as expansive cell nests surrounded by collagen fibers. In 
contrast, melanoma cells of M7 tumor infiltrated the underlying dermis diffusely, suggestive 
of high collagenolytic activity. Consistently with prominent lymphatic invasion, M4 patient 
had macrometastases in all lymph nodes analyzed, as well as distant metastases, whereas no 
lymph node metastases were observed in M7 patient. These results suggest that MT3-MMP 








1. The release of ECM-bound large latent TGF-β complex by MT1-MMP 
(I) 
 
TGF-β regulates a wide array of cellular functions, including angiogenesis. It is essential for 
both the initial phases of endothelial sprouting, and the resolution and maturation phase of the 
angiogenesis. The activation of TGF-β is tightly regulated by various mechanisms. TGF-β is 
targeted to ECM via large latent TGF-β complex (LLC), which release from the ECM 
promotes TGF-β activation. We explored the endogenous mechanisms of LLC release from 
the ECM in endothelial cells. We found that following morphological activation of 
endothelial cells by PMA, MT1-MMP expression and activity is induced, with concomitant 
release of ECM-bound LTPB-1 and LLC. Silencing of MT1-MMP with lentiviral shRNA 
abrogated this release. The release of LLC was cell type specific, since treatment of human 
lung fibroblasts with PMA failed to induce LTBP-1 and LLC depletion from the ECM. In 
addition, LTBP-2 cleavage was not observed, indicating that morphological activation of 
endothelial cells was associated specifically with LTBP-1 cleavage. 
Both MT1-MMP and TGF-β have been implicated in angiogenesis. MT1-MMP is 
specifically expressed in sprouting tip during neovessel formation, where it acts as a 
collagenase. In contrast, vascular smooth muscle cells suppress MT1-MMP activity in mature 
and stabilized vessels (Yana et al., 2007). Recently, some of the MT1-MMP functions in 
angiogenesis have been reported to be mediated by TGF-β activation. For example, 
prostaglandin E2 induces MT1-MMP clustering on the endothelial cell surface, which leads to 
TGF-β activation and induction of angiogenesis (Alfranca et al., 2008). Further, MT1-MMP 
knockout mice exhibit decreased levels of total TGF-β and defects in angiogenesis. 
Consistently, mice with mutated cleavage resistant Col1α1(I) and upregulated MT1-MMP 
activity display increased active TGF-β, which results in enhanced vascular leakage (Sounni 
et al., 2010). We could not confirm TGF-β activation in our experimental conditions, 
probably due to the low levels of active TGF-β. The phosphorylation of Smad2/3, the 
downstream effector of TGF-β signalling, was not observed in activated endothelial cells. 
However, since the release of latent TGF-β is the first step in its activation, our results 
demonstrate that MT1-MMP increases the bioavailability of latent TGF-β, which could be 
activated in the physiological microenvironment. Consistently, the activation of TGF-β 
secreted by endothelial cells may require the presence of smooth muscle cells (Sato et al., 
1993). 
According to previous reports, serine proteases and secreted MMPs can activate TGF-β 
(Dallas et al., 2002; Yu and Stamenkovic, 2000). However, neither of them was involved in 
LTPB-1 cleavage in our results, since serine protease inhibitors or TIMP-1, which targets 
secreted MMPs, did not affect LTBP-1 depletion from the ECM. PKC pathway is essential for 
mediating angiogenic signals. VEGF induces Erk1/2 phosphorylation via PKC kinase leading 
to increased endothelial cell proliferation (Wong and Jin, 2005). We observed marked 
induction in Erk1/2 phosphorylation downstream of PKC. Both PKC and MEK inhibitors 
abrogated endothelial cell morphology change and LTBP-1 release from the ECM. Therefore, 
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LLC release from the ECM can be general feature of endothelial cells activated to proliferate 
or engage in sprouting morphogenesis. 
 
2. Interrelated functions of MT1-MMP and MT3-MMP in melanoma cell 
invasion (II, III) 
 
MT-MMPs are well-recognized players in cancer progression. In addition to cleaving ECM 
proteins, they can activate secreted MMPs by cleaving their prodomains. We observed 
previously uncharacterized type of interaction between two MT-MMPs. MT3-MMP reduced 
cell surface localization and collagenolytic activity of MT1-MMP. Despite MT1-MMP and 
MT3-MMP being close homologues (66% homology of amino acid sequence of catalytical 
domain, (Takino et al., 1995)), their different substrate specificity for collagen type I, the 
most abundant protein in human body, results in strikingly different biological functions when 
expressed in tumor cells. Since MT3-MMP is not merely unable to cleave collagen type I, but 
also reduces collagenolytic activity of MT1-MMP, its expression has profound effects on the 
growth and invasion phenotype of tumor cells. On the other hand, MT3-MMP can promote 
melanoma cell invasion in fibrin even more efficiently than MT1-MMP, indicating that the 
net effect of MT3-MMP on melanoma cell invasion depends on the surrounding tissue. 
We found that MT3-MMP reduces MT1-MMP cell surface levels both in vitro (II) and 
in vivo (III), providing another mechanism for posttranslational regulation of MT1-MMP 
protein expression and subcellular localization. When co-expressed in COS or Bowes cells, 
MT3-MMP induced MT1-MMP cleavage to 44 kDa fragment, which corresponds to the 
fragment generated by autocatalytic cleavage, and 37 kDa fragment. The smaller fragment has 
been reported before to be generated by recombinant MMP-2, MMP-3, MMP-13, and soluble 
MT1-MMP (Stanton et al., 1998), which may represent another cleavage site accessed by 
other MMPs but not by cell surface MT1-MMP itself. Cleavage of endogenous MT1-MMP 
was not detected in WM852 cells, probably due to high levels of TIMP-2 and TIMP-3 in 
these cells (Airola et al., 1999), or rapid internalization of 44 kDa cleaved fragment. However, 
MT3-MMP reduced full-length cell surface MT1-MMP also in WM852 cells. Co-expression 
of catalytically inactive MT3-MMP mutant did not induce MT1-MMP cleavage, affect cell 
surface localization of MT1-MMP, or reduce MT1-MMP-driven collagen invasion. 
Therefore, MT3-MMP catalytical activity is required for the regulation of MT1-MMP cell 
surface localization either directly by inducing its cleavage and internalization, or indirectly 
by affecting MT1-MMP trafficking.  
Reduced cell surface MT1-MMP correlated with decreased invasiveness in collagen in 
vitro (II) and collagen accumulation in tumors in vivo (III). MT3-MMP expressing melanoma 
xenografts displayed slow restricted growth (III). This suggests that limited ability of MT3-
MMP expressing cells to cleave collagen type I resulted in collagen accumulation and tumor 
growth restriction. In contrast, the opposite pattern of fibrin accumulation was observed. 
Although both MT1-MMP and MT3-MMP cleave fibrin, extracellular fibrin network was 
observed only in tumors with silenced MT3-MMP, suggesting that MT3-MMP is more potent 
enzyme to cleave fibrin in these cells than MT1-MMP. Since fibrin is a component of the 
provisional matrix often observed at tumor/host interface and perivascular spaces, MT3-MMP 
may promote tumor dissemination by driving cell invasion through fibrin-rich tissues.  
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In human melanoma tumors, low MT1-MMP and high MT3-MMP expression 
correlated with cohesive growth of melanoma cell nests, which grew expansively pushing 
collagen fibers outwards (III). In two human melanoma tumors with high MT1-MMP and low 
MT3-MMP expression, melanoma cells infiltrated underlying dermis diffusely, and did not 
form cell nests, suggesting that the expression of both MT1-MMP and MT3-MMP may 
determine the net collagenolytic activity, and growth phenotype. Since MT1-MMP affects 
many cell-cell and cell-ECM adhesive proteins, it is possible that cohesive vs. infiltrating 
phenotype of melanoma cells was affected, in addition to collagenolytic ability, by cell-cell 
contacts. 
Interestingly, MT3-MMP is specifically upregulated in the most aggressive subtype of 
melanoma, namely nodular melanoma (Jaeger et al., 2007; Ohnishi et al., 2001). This may 
seem unexpected since melanoma grows in collagen-rich skin and may thus depend on 
unperturbed MT1-MMP activity. Nodular melanomas are typically small nodular tumors, 
which lack radial growth phase, and grow rapidly in thickness instead, having metastasizing 
capacity already at the early stages. In 3D collagen culture of seven melanoma cell lines, 
MT3-MMP expression was associated with expansive spherical growth, contrasted by the 
invasive sprouting growth of melanoma cell lines without MT3-MMP (II). This phenotype 
was found to be MT3-MMP-dependent, since silencing MT3-MMP in two melanoma cell 
lines resulted in the shift from expansive to invasive growth. Thus, MT3-MMP does not 
inhibit colony growth in 3D collagen, but rather affects the growth pattern, indicating that low 
MT1-MMP activity is still present at the cell surface. Consistently, cell surface levels of 
MT1-MMP determine the invasive vs. expansive growth phenotype of ovarian carcinoma 
cells (Moss et al., 2009), suggesting that MT3-MMP regulates melanoma growth phenotype 
by affecting MT1-MMP cell surface activity. 
In addition, MT3-MMP expressing WM852 cells grew as adherent monolayers in 2D 
culture, while MT3-MMP silencing rendered them to elongated single cells (III). MT1-MMP 
expression and induced collagenolytic activity and invasion are linked to epithelial-to-
mesenchymal transition-like phenotype observed at the initial stages of many carcinomas (Ota 
et al., 2009). Mesenchymal-like single cell invasion may facilitate local spreading and 
intravasation, but it impedes metastatic colony formation at the distant sites. Instead, 
carcinoma cells must return to the epithelioid phenotype at the late stages of metastatic 
process to be able to form adhesive colonies in the distant organs (Polyak and Weinberg, 
2009). Furthermore, cells which engage in collective invasion and grow as cohesive colonies 
colonize distant organs more efficiently than those moving in a single cell manner (Chui, 
2012; Friedl and Gilmour, 2009; Giampieri et al., 2009). Therefore, MT3-MMP expression 
may give advantage to nodular melanomas by suppressing excessive MT1-MMP activity and 
promoting adhesive phenotype of melanoma cells. We observed upregulation of MT3-MMP 
expression in two out of eight human melanoma biopsies (III), in biopsies of human 
melanoma lymph node metastases (II), and in three out of four metastatic melanoma cell lines 






3. MT3-MMP in vascular invasion of melanoma cells (III) 
 
Solid tumors disseminate to distant organs either via lymphatic or blood vessels. Some 
tumors, such as melanoma and breast cancer, spread mainly via lymphatics, first to tumor 
draining sentinel lymph nodes, and further to the other lymph nodes, circulation, and distant 
organs. In our results, MT3-MMP expression was associated with prominent lymphatic 
invasion (LVI), while MT3-MMP silencing abrogated LVI and shifted melanoma cell 
invasion towards blood vessel invasion (BVI). Enhanced BVI correlated with increased cell 
surface MT1-MMP and collagen degradation.  
The mechanisms of tumor cell intravasation and its contribution to metastatic 
progression are widely debated issues. Since the amount of circulating tumor cells does not 
correlate with the metastatic colony formation, it has been proposed that tumor cell 
intravasation is not a rate-liming step for metastatic dissemination (Butler and Gullino, 1975; 
Fidler, 2003). Furthermore, discontinuous basement membrane and defects in endothelial cell 
lining in tumor vessels could allow the passive passage into the blood vessels without need of 
active invasion or proteolytic activity (Bockhorn et al., 2007; Hashizume et al., 2000). 
However, others report that blood vessel intravasation requires active permeabilization of the 
vessel wall by tumor cells, and that MT1-MMP activity is involved in this process (Perentes 
et al., 2011; Shen et al., 2010; Stoletov et al., 2007). We find that in melanoma xenografts 
blood vessel invasion is restricted when collagen type I is accumulated around the blood 
vessels in tumors with low MT1-MMP activity, suggesting that active proteolytic activity is 
required for BVI, at least in collagen-rich environment. Taken together, reduced BVI in MT3-
MMP expressing tumors may reflect both the reduced invasion towards the blood vessels, and 
the limited ability to induce blood vessel permeabilization due to low MT1-MMP activity.  
According to The Human Protein Atlas, MT3-MMP protein is expressed moderately in 
normal human keratinocytes, and weakly in fibroblasts and melanocytes in the skin 
(www.proteinatlas.org). Out of twenty cancer tissues examined in the Atlas, the highest 
protein expression was observed in melanoma biopsies (in 50% of which the staining was 
strong, in 42% - moderate and in 8% - weak), suggesting that MT3-MMP is involved in 
melanoma pathogenesis. We observed high MT3-MMP expression in two out of eight human 
melanoma biopsies. While the nodular vs. superficially spreading origin of melanoma 
biopsies was not defined, the expression frequency of MT3-MMP resembled the occurrence 
of nodular melanoma (~15% of melanoma cases).  Prominent lymphatic vessel invasion was 
observed in the human tumor with high MT1-MMP and MT3-MMP expression, as compared 
to no lymphatic invasion in the tumor with high MT1-MMP and low MT3-MMP expression.  
Clear correlation between lymphatic invasion with poor outcome in breast cancer and 
melanoma patients  suggests that lymphatic vessel invasion may be essential for metastatic 
progression of certain cancers (Egger et al., 2011; Niakosari et al., 2008; Petersson et al., 
2009; Ran et al., 2010; Rose et al., 2011). Since lymphatic vessels lack basement membrane, 
pericyte lining, and exhibit intraendothelial channels, lymphatic vessel invasion could occur 
passively. The preference to invade into blood vs. lymphatic vessels depends also on the 
adhesive phenotype of the cells. Thus, tumor cells invading in single cell manner intravasate 
into blood vessels, while cells engaging in collective invasion enter lymphatic vessels 
(Giampieri et al., 2009). We found that MT3-MMP induced the adhesive phenotype of 
melanoma cells, which may provide an advantage for LVI, while MT3-MMP silencing 
resulted in elongated single cell growth pattern. We did not observe any macrometastases in 
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our xenograft models, probably due to the short follow up period and low metastatic ability of 
the cell line used. However, the observed shift in the initial stage of metastatic dissemination 
from LVI to BVI in MT3-MMP silenced cells provides new insights to the factors which 
modulate intravasation process. 
Metastatic melanoma is a disease which is highly resistant to current treatments. 
Recently, B-raf inhibitors have been accepted to treat metastatic melanoma with BRAF 
mutations. However, ~50-60% of melanomas do not harbour this mutation (Lee et al., 2010), 
emphasizing a need to explore the biology of BRAF-wild type tumors. WM852 cells used in 
this study are wild type for BRAF, but have mutated NRAS, consistently with the observation 
that BRAF mutation frequently occurs in slowly progressing superficially spreading 
melanoma, while mutated NRAS is seen more often in aggressive nodular melanomas (Lee et 
al., 2010), from which WM852 cells are originating. 
Sentinel lymph node (SLN) biopsy, a standard procedure for ≥1 mm thick melanomas, 
is associated with increased morbidity without improving overall survival (Morton et al., 
2006). In addition, the fraction of thin (<1 mm) melanomas will eventually form distant 
metastases. Therefore, new markers which can be assessed already from the primary tumor 
helping to predict SLN and distant metastasis, and to find patients who would benefit from 
lymphadenectomy are needed (Shields et al., 2004). Shields et al proposed the use of Shields 
index, which combines lymphatic density, Breslow thickness and LVI, and predicts metastatic 
status even more accurately than Breslow thickness alone (Emmett et al., 2010; Shields et al., 
2004). We found here that MT3-MMP expression is associated with LVI, suggesting that 
MT3-MMP might also predict melanoma metastatic dissemination. 
LVI is observed in 16-63% of melanoma samples and correlates with lymph node 
metastasis and poor survival of melanoma patients (Egger et al., 2011; Niakosari et al., 2008; 
Petersson et al., 2009; Rose et al., 2011). By contrast, BVI, detected in 3-43% of melanoma 
samples, does not correlate with melanoma progression or prognosis (Storr et al., 2012). LVI 
correlates also with the aggressive nodular melanoma subtype, where MT3-MMP is 
specifically expressed (Jaeger et al., 2007; Storr et al., 2012). Taken together, since MT3-
MMP is associated with nodular melanoma subtype (Jaeger et al., 2007; Ohnishi et al., 2001), 
lymph node metastasis (II), and LVI (III), its expression may predict poor prognosis of 








Figure 7. The main results of the thesis. MT1-MMP expressed by endothelial cells releases 
ECM-bound large latent TGF-β complex by inducing the cleavage of LTBP-1, which N-
terminal region is bound to ECM proteins. MT3-MMP cleaves MT1-MMP leading to reduced 
collagen degradation and blood vessel invasion of melanoma cells, as well as motility shift 
from single cell to collective migration. Collagen accumulation and collective motility impair 
blood vessel invasion, but facilitate lymphatic vessel invasion.  
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MT1-MMP and TGF-β are involved in neovessel formation. MT1-MMP is specifically 
expressed at the sprouting tips of growing vessels. TGF-β is secreted from endothelial cells as 
a large latent TGF-β complex, which targets it to the ECM. The data presented here identifies 
MT1-MMP as an enzyme which has the ability to release large latent TGF-β complex from 
the ECM of endothelial cells (Fig. 7). MT1-MMP cleaved LTBP-1 from the ECM after 
endothelial cell activation by a protein kinase C agonist, PMA. Since protein kinase C 
mediates angiogenic signals of VEGF and FGF, MT1-MMP-mediated TGF-β release may be 
a general mechanism to increase bioavailability of TGF-β during angiogenesis. 
MT1-MMP is a potent collagenase which drives tumor cell invasion through basement 
membranes and collagen-rich interstitial tissues. MT3-MMP is a close homologue to MT1-
MMP, but it cannot cleave collagen type I. We found here that MT3-MMP restricts the 
collagenolytic activity of MT1-MMP by reducing its cell surface levels both in vitro and in 
vivo. This results in decreased collagen invasion, but induces growth of cohesive colonies in 
vitro. Limited collagenolytic ability and cohesive growth impair blood vessel invasion of 
melanoma cells, but permit their lymphatic invasion. Taken together, MT3-MMP expression 
correlates with lymphatic vessel invasion, a process associated with poor prognosis of 
melanoma patients (Fig. 7). The elucidation of the mechanisms of lymphatic invasion by 
tumor cells can help to discover new prognostic markers for metastatic dissemination, and 
facilitate the development of specific intravasation inhibitors. The correlation of MT3-MMP 
expression of melanoma tumors with metastatic progression or patient survival should bring 
valuable information of MT3-MMP functions in in vivo melanoma progression. In the coming 
era of personalized medicine, when gene sequencing of individual tumors will be widely 
performed, the information about key modifiers of tumor progression will accumulate and 
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